1
|
Wang M, Qin L, Bao W, Xu Z, Han L, Yan F, Yang W. Epicardial and pericoronary adipose tissue and coronary plaque burden in patients with Cushing's syndrome: a propensity score-matched study. J Endocrinol Invest 2024:10.1007/s40618-023-02295-x. [PMID: 38308163 DOI: 10.1007/s40618-023-02295-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Accepted: 12/28/2023] [Indexed: 02/04/2024]
Abstract
PURPOSE To assess coronary inflammation by measuring the volume and density of the epicardial adipose tissue (EAT), perivascular fat attenuation index (FAI) and coronary plaque burden in patients with Cushing's syndrome (CS) based on coronary computed tomography angiography (CCTA). METHODS This study included 29 patients with CS and 58 matched patients without CS who underwent CCTA. The EAT volume, EAT density, FAI and coronary plaque burden were measured. The high-risk plaque (HRP) was also evaluated. CS duration from diagnosis, 24-h urinary free cortisol (UFC), and abdominal visceral adipose tissue volume (VAT) of CS patients were recorded. RESULTS The CS group had higher EAT volume (146.9 [115.4, 184.2] vs. 119.6 [69.0, 147.1] mL, P = 0.006), lower EAT density (- 78.79 ± 5.89 vs. - 75.98 ± 6.03 HU, P = 0.042), lower FAI (- 84.0 ± 8.92 vs. - 79.40 ± 10.04 HU, P = 0.038), higher total plaque volume (88.81 [36.26, 522.5] vs. 44.45 [0, 198.16] mL, P = 0.010) and more HRP plaques (7.3% vs. 1.8%, P = 0.026) than the controls. The multivariate analysis suggested that CS itself (β [95% CI], 29.233 [10.436, 48.03], P = 0.014), CS duration (β [95% CI], 0.176 [0.185, 4.242], P = 0.033), and UFC (β [95% CI], 0.197 [1.803, 19.719], P = 0.019) were strongly associated with EAT volume but not EAT density, and EAT volume (β [95% CI] - 0.037[- 0.058, - 0.016], P = 0.001) not CS was strongly associated with EAT density. EAT volume, FAI and plaque burden increased (all P < 0.05) in 6 CS patients with follow-up CCTA. The EAT volume had a moderate correlation with abdominal VAT volume (r = 0.526, P = 0.008) in CS patients. CONCLUSIONS Patients with CS have higher EAT volume and coronary plaque burden but less inflammation as detected by EAT density and FAI. The EAT density is associated with EAT volume but not CS itself.
Collapse
Affiliation(s)
- M Wang
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - L Qin
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - W Bao
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - Z Xu
- Siemens Healthineers CT Collaboration, Shanghai, China
| | - L Han
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - F Yan
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - W Yang
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China.
| |
Collapse
|
2
|
Wu R, Lv P, Liu B, Bai Y, Wang J, Wei J, Su W, Xu G, Bao W, Yu G. Aromatics production from relay catalytic pyrolysis of cow manure using Ru/C and ZSM-5 dual catalysts synthesized from coal gasification fine slag. J Environ Manage 2023; 348:119356. [PMID: 37883835 DOI: 10.1016/j.jenvman.2023.119356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 09/25/2023] [Accepted: 10/14/2023] [Indexed: 10/28/2023]
Abstract
Resource utilization of solid waste can aid in gradual substitution of fossil fuels while achieving waste recycling. In this study, residual carbon and ash slag from the coal gasification fine slag were separated by froth flotation, and then was used to prepare Ru/C and ZSM-5 dual catalysts with carbon-rich and ash-rich components as raw materials, respectively. The performance of two catalysts for catalytic upgrading of volatiles from pyrolysis of cow manure (CM) to produce light aromatic hydrocarbons was systematically investigated. The direct pyrolysis products of CM mainly included alcohols, ketones, ethers, and other oxygen-containing compounds. When ZSM-5 was used as the catalyst, the yield of monocyclic aromatic hydrocarbons (MAHs) increased significantly due to the better catalytic cracking and aromatization abilities of ZSM-5 catalyst. However, the yield of phenols in the pyrolysis products improved when Ru/C was used as the catalyst due to the cleavage effect of Ru/C on the C-O bond. When Ru/C and ZSM-5 were used as dual catalysts in relay catalytic pyrolysis of volatiles, the increase in MAHs yield in the pyrolysis product was higher than the total increase obtained under Ru/C and ZSM-5 single catalysis. The possible pathways for the generation of MAHs from CM under Ru/C and ZSM-5 relay catalytic pyrolysis were revealed by the pyrolysis experiment performed on model compounds.
Collapse
Affiliation(s)
- Ruofei Wu
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China
| | - Peng Lv
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China.
| | - Bin Liu
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China
| | - Yonghui Bai
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China
| | - Jiaofei Wang
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China
| | - Juntao Wei
- Joint International Research Laboratory of Biomass Energy and Materials, Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Materials Science and Engineering, Nanjing Forestry University, Nanjing, 210037, China
| | - Weiguang Su
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China
| | - Guangyu Xu
- Shandong Yankuangguotuo Science & Engineering Co., Ltd., Zoucheng, 273500, China
| | - Weina Bao
- Shandong Yankuangguotuo Science & Engineering Co., Ltd., Zoucheng, 273500, China
| | - Guangsuo Yu
- State Key Laboratory of High-Efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China; Institute of Clean Coal Technology, East China University of Science and Technology, Shanghai, 200237, China.
| |
Collapse
|
3
|
Gao Y, Wang M, Raheem A, Wang F, Wei J, Xu D, Song X, Bao W, Huang A, Zhang S, Zhang H. Syngas Production from Biomass Gasification: Influences of Feedstock Properties, Reactor Type, and Reaction Parameters. ACS Omega 2023; 8:31620-31631. [PMID: 37692248 PMCID: PMC10483670 DOI: 10.1021/acsomega.3c03050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 08/08/2023] [Indexed: 09/12/2023]
Abstract
Syngas from biomass gasification can be used in downstream process industries such as city gas, hydrogen production, etc. In this review, the effects of biomass feedstock properties, and gasification reaction conditions (temperature, gasifier type, etc.) on syngas properties are systematically reviewed. In summary, the cracking and reforming of volatile fractions in the gasification process and the catalytic effect of alkali and alkaline earth metals in the ash on the gasification have a direct impact on the syngas yield. And biomass pretreatment (i.e., terrifying/hydrothermal carbonization) can reduce the moisture content, which can effectively reduce the energy required for gasification and enhance the calorific value and syngas yield further. The fixed-bed gasifiers produce lower amounts of syngas. The concentration of H2 is significantly increased by adding steam as a gasification agent. Additionally higher gasification temperatures produce more syngas, and an equivalence ratio of about 0.2-0.3 is considered suitable for gasification. For the influence of feedstock on syngas, this paper not only reviews the feedstock properties (volatile, ash, moisture) but also compares the influence of two pretreatments on syngas yield and proposes that the combination of torrefaction/hydrothermal carbonization and a multistage air bed gasifier is an important research direction to improve the combustible components of syngas. In addition to the summary of commonly used single gasification agents, two or more gasification agents on the concentration of syngas components are also discussed in the gasification parameters, and it is suggested that further research into the use of more than one gasification agent is also important for future syngas production.
Collapse
Affiliation(s)
- Yali Gao
- Joint
International Research Laboratory of Biomass Energy and Materials,
College of Materials Science and Engineering, Nanjing Forestry University, Nanjing 210037, People’s Republic of China
| | - Miao Wang
- Joint
International Research Laboratory of Biomass Energy and Materials,
College of Materials Science and Engineering, Nanjing Forestry University, Nanjing 210037, People’s Republic of China
| | - Abdul Raheem
- Department
of Electrical Engineering, Sukkur IBA University, Sukkur Sindh 65200, Pakistan
| | - Fuchen Wang
- National
Engineering Research Center for Coal Slurry Gasification and Coal
Chemical Industry (Shanghai), East China
University of Science and Technology, Shanghai 200237, People’s Republic of China
| | - Juntao Wei
- Joint
International Research Laboratory of Biomass Energy and Materials,
College of Materials Science and Engineering, Nanjing Forestry University, Nanjing 210037, People’s Republic of China
- State
Key Laboratory of High-efficiency Utilization of Coal and Green Chemical
Engineering, College of Chemistry and Chemical Engineering, Ningxia University, Yinchuan 750021, People’s Republic of China
- Shandong
Yankuang Guotuo Technology Engineering Co., Ltd, Jinan 250101, People’s Republic of China
| | - Deliang Xu
- Joint
International Research Laboratory of Biomass Energy and Materials,
College of Materials Science and Engineering, Nanjing Forestry University, Nanjing 210037, People’s Republic of China
| | - Xudong Song
- State
Key Laboratory of High-efficiency Utilization of Coal and Green Chemical
Engineering, College of Chemistry and Chemical Engineering, Ningxia University, Yinchuan 750021, People’s Republic of China
| | - Weina Bao
- Shandong
Yankuang Guotuo Technology Engineering Co., Ltd, Jinan 250101, People’s Republic of China
| | - Ankui Huang
- Marssenger
Kitchenware Co., Ltd, Jiaxing 314400, People’s
Republic of China
| | - Shu Zhang
- Joint
International Research Laboratory of Biomass Energy and Materials,
College of Materials Science and Engineering, Nanjing Forestry University, Nanjing 210037, People’s Republic of China
| | - Hong Zhang
- Joint
International Research Laboratory of Biomass Energy and Materials,
College of Materials Science and Engineering, Nanjing Forestry University, Nanjing 210037, People’s Republic of China
| |
Collapse
|
4
|
D’Agostino MA, Boers M, Gaillez C, Gamez C, Ventura L, Rosa J, Padovano I, Mandl P, Kleyer A, Bakewell C, Bao W, Goyanka P, Conaghan PG, Schett G. OP0260 RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO csDMARDs: DATA FROM THE ULTIMATE TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPower Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool that allows the visualisation of articular and periarticular inflammation in patients with psoriatic arthritis (PsA).1 ULTIMATE (NCT02662985) was the first large randomised clinical trial that showed the responsiveness of the Global OMERACT-EULAR ultrasound synovitis score (GLOESS) in PsA and confirmed the rapid and continued benefits of secukinumab through 52 weeks.2,3ObjectivesTo report the distribution of ultrasound-detected synovitis at joint level, by degree of severity at baseline and over time, and the contribution of each core component of GLOESS, synovial hypertrophy (SH) by greyscale (GS; B-mode) and power Doppler (PD) signal, to responsiveness.3MethodsThis was a 52-week study with a 12-week double-blind, placebo-controlled treatment period followed by a 12-week open-label period and a 6-month open-label extension secukinumab treatment period.3 The number of joints with synovitis measured by GLOESS2 was assessed up to Week 52. The assessments included distribution of synovitis based on composite PDUS score across 24 pairs of joints (with worse score of the pair of the joints used) by grade of severity (0-3) and change from baseline to Week 52 in each core component of GLOESS.3-5 Data are presented as observed.ResultsA total of 166 patients (mean age, 46.7 years; males, 45.2%) were enrolled, of which 90% (75/83) of secukinumab and 83% (69/83) of placebo-secukinumab participants completed 52 weeks. The mean (SD) number of PDUS detected synovitis at baseline was 9.2 (4.9) and 10.2 (5.2) in the secukinumab and placebo group, respectively. The most frequent locations with synovitis at baseline were: wrist, metatarsophalangeal (MTP), knees and metacarpophalangeal (MCP) joints (Table 1). An early and continued improvement in GLOESS was observed in both secukinumab and placebo-secukinumab groups after switching to active therapy, as previously reported at Week 12 and through Week 52.2,3 Among the two core components of GLOESS, SH was mainly responsible for the change in GLOESS from baseline to Week 52, in contrast with PD signal in this dataset. The distribution of synovitis by grade of severity showed that MTP joints, wrist, knee, MCP1/2 and tibiotalar joints mostly contributed to the composite PDUS at Week 12 (Figure 1). Similar patterns were observed through 52 weeks.Table 1.Proportion of patients with PDUS detected synovitis at baseline*Synovitis joint, data presented as n (%)Secukinumab (N=83)Placebo (N=83)Wrist66 (80)66 (80)MTP256 (68)65 (78)MTP158 (70)60 (72)MTP352 (63)60 (72)MTP446 (55)59 (71)Knee50 (60)47 (57.)MCP136 (43)52 (63)MCP235 (42)41 (49)MTP530 (36)41 (49)*Data for top nine pairs of joints with most frequently detected power Doppler ultrasound (PDUS) synovitis are presented here. Synovitis was scored by a OMERACT-EULAR synovitis composite score >0 for each paired joint (irrespective of right or left side). The OMERACT-EULAR composite PDUS score (for individual joints) ranged from 0 to 3 and was composed of the two core components synovial hypertrophy and power Doppler.N, total number of randomised patients; n, number of evaluable patientsConclusionThe distribution of synovitis at baseline reflected a predominance of small joints (feet and hands) and large joints (wrist and knee) and were mostly responsive to secukinumab over time in the ULTIMATE trial. Synovial hypertrophy was the most responsive core component of GLOESS driving an early and continued reduction of synovitis with secukinumab through Week 52. This finding could be useful to select a restricted number of joints in future ultrasound trials in PsA.References[1]D’Agostino MA and Coates LC. J Rheumatol. 2019;46:337–9.[2]D’Agostino MA et al. Arthritis Rheumatol. 2021;73(10).[3]D’Agostino MA, et al. Rheumatology (Oxford) 2021;keab628.[4]D’Agostino MA and Coates LC. RMD Open 2017;3:e000428.[5]Uson J, et al. Rheumatol Clin. 2018;14:27–35.Disclosure of InterestsMaria-Antonietta D’Agostino Speakers bureau: Sanofi, Novartis, BMS, Janssen, Celgene, Roche, AbbVie, UCB, and Eli Lilly, Consultant of: Sanofi, Novartis, BMS, Janssen, Celgene, Roche, AbbVie, UCB, and Eli Lilly, Maarten Boers Consultant of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis, Carlos Gamez: None declared, LUCIO VENTURA: None declared, Javier Rosa Speakers bureau: Abbvie, Pfizer, Lilly, Janssen, Novartis and BMS, Ilaria Padovano: None declared, Peter Mandl Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB, Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB, Arnd Kleyer Speakers bureau: Abbvie, Lilly, Novartis, MEDAC; Janssen, Consultant of: Abbvie, Lilly, UCB, Novartis, BMS, Sanofi, Galapagos, Catherine Bakewell Speakers bureau: AbbVie, Novartis, Pfizer, Janssen, UCB, and Sanofi Genzyme/Regeneron, Consultant of: AbbVie, Novartis, Pfizer, Janssen, UCB, and Sanofi Genzyme/Regeneron, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Punit Goyanka Employee of: Novartis, Philip G Conaghan Speakers bureau: AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche and UCB
Collapse
|
5
|
D’Agostino MA, Boers M, Schett G, Conaghan PG, Naredo E, Mandl P, Carron P, Backhaus M, López-Rodríguez A, Hanova P, Goyanka P, Sahoo BG, Gaillez C, Bao W. OP0294 REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe combined use of B-mode ultrasound (US) and Power Doppler (PD; combination termed as PDUS) allows visualisation of morphological and pathophysiological changes of the synovium. ULTIMATE (NCT02662985) was the first large, randomised, double-blind, placebo-controlled PDUS phase IIIb study in psoriatic arthritis (PsA), to demonstrate that Global OMERACT EULAR Synovitis Score (GLOESS), a US score at patient level, was sensitive to detect the early and continuous decrease in synovitis in a multicenter setting using different US devices and examiners.1 However, the US assessment for GLOESS was time-consuming owing to the number of joints assessed.ObjectivesTo investigate the value of various reduced joint sets to predict the validated GLOESS score.MethodsULTIMATE was a 52-week study with a 12-week double-blind, placebo-controlled period followed by 12-week open-label (OL) treatment and 6-month OL extension period.1 In the ULTIMATE trial, GLOESS for the 24 paired joints was calculated, with a potential score ranging between 0 to 144.1 A Spearman’s rank correlation matrix and a Cluster Image Map were constructed to identify highly correlated joint clusters based on the composite PDUS scores. Based on the different approaches (best correlation, model optimization, etc.), representative joints were then selected from each group, which yielded several corresponding combinations of joints. Linear models were developed with these reduced joint sets as predictors of GLOESS, using data from 60% of patients randomly selected from the ULTIMATE study. The remaining 40% data were used for model validation and diagnostics.ResultsFive models were established with reduced pairs of joint sets (9–13 pairs). The joints included in each linear model are summarized in Table 1. All five models of reduced joint sets showed high correlation with GLOESS score of R2 ~ 0.95. Figure 1 depicts all the 5 models of reduced joint sets for PDUS-detected synovitis versus the actual GLOESS in secukinumab and placebo-secukinumab groups, with modified GLOESS scores using reduced PDUS joint sets demonstrating changes very close to that of validated GLOESS.Table 1.Joints included across five linear models, indicated by green shadingJoint pairsModel 1 (N=9)Model 2 (N=9)Model 3 (N=9)Model 4 (N=13)Model 5 (N=12)ElbowKneeMTP2WristMCP1DIP4MTP4MCP2MCP4MCP5PIP3PIP4PIP1, PIP5DIP2DIP3, DIP5MTP1MTP5ShoulderTibiotalarN, number of joint pairs used in model. DIP, distal interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal;PIP, proximal interphalangealFigure 1.Reduced set of joints synovitis score vs GLOESS scoreConclusionAll models of reduced joint sets for PDUS-detected synovitis predicted GLOESS well. The next steps will be to document responsiveness and ability to discriminate between active and placebo treatment.References[1]D’Agostino MA, et al. Rheumatology (Oxford) 2021;keab628.Disclosure of InterestsMaria-Antonietta D’Agostino Speakers bureau: AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, and UCB, Consultant of: AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, and UCB, Maarten Boers Consultant of: BMS, GSK, Novartis, Pfizer, Consultant of: BMS, GSK, Novartis and Pfizer, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche and UCB, Philip G Conaghan Speakers bureau: AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Consultant of: AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Esperanza Naredo Speakers bureau: AbbVie, BMS, Celgene GmbH, Janssen, Lilly, Novartis, Pfizer, Roche, UCB, Grant/research support from: Honoraria for clinical trials from Abbvie, BMS and Novartis; Research Grants from Lilly, Peter Mandl Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB., Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB., Philippe Carron Speakers bureau: AbbVie, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Gilead, Merck Sharp Dohme, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Gilead, Merck Sharp Dohme, Novartis, Pfizer, and UCB, Grant/research support from: Merck Sharp Dohme, Pfizer and UCB, Marina Backhaus Speakers bureau: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche, UCB, Grant/research support from: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche, UCB, Alejandra López-Rodríguez Speakers bureau: Eli Lilly, GSK, Janssen, Novartis, Roche and UCB, Consultant of: Eli Lilly, GSK, Janssen, Novartis, Roche and UCB, Petra Hanova: None declared, Punit Goyanka Employee of: Novartis, Braja Gopal Sahoo Employee of: Novartis, Corine Gaillez Shareholder of: Shareholder of Novartis and BMS, Employee of: Novartis, Weibin Bao Employee of: Novartis
Collapse
|
6
|
Felten R, Widawski L, Spielmann L, Gaillez C, Bao W, Gottenberg JE, Duret PM, Messer L. POS1065 IMPACT OF HYPERURICEMIA ON CLINICAL PHENOTYPE, COMORBIDITIES, AND RESPONSE TO SECUKINUMAB IN PSORIATIC ARTHRITIS: POST HOC ANALYSIS OF FUTURE AND MAXIMISE STUDIES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundHyperuricemia (HU) is a metabolic abnormality associated with psoriasis (PsO) and psoriatic arthritis (PsA)1. The prevalence of HU is 2–13% in general population, 19–20% in PsO patients (pts), and 27–32% in PsA pts1,2. Pts with PsO/PsA are at significantly increased risk of HU and development of gout1. The pathogenic role of chronic HU in the development and maintenance of PsA is based on epidemiological, clinical, and fundamental arguments and hence does not appear fortuitous. These processes can influence each other3. Moreover, PsA with HU has been shown to be more peripheral, destructive, and challenging to treat4.ObjectivesTo evaluate the impact of HU on PsA in terms of clinical presentation, severity, comorbidities, and response to secukinumab (SEC) over 1-year.MethodsThis post hoc analysis included pooled data from PsA pts enrolled in the FUTURE 2–5 and MAXIMISE phase 3 trials. Pts were stratified into 2 groups based on baseline (BL) serum uric acid (SUA) level (HU: ≥360 µmol/L; without HU: <360 µmol/L and no history of gout and/or uric acid lowering therapies [ULT]). Demographic and disease characteristics, PsA and therapeutic history, and comorbidities data, were collected at BL. Evaluations included ACR20/50/70 responses, Psoriasis Area and Severity Index (PASI) 90 response, resolution of enthesitis and dactylitis, Health Assessment Questionnaire Disability Index (HAQ-DI), and mean change in SUA level, up to Week 52. All analyses were performed at a descriptive level and data presented as observed.ResultsOverall, 2504 PsA pts were included in the analysis, of which 822 (32.8%) had HU (62 [2.5%] with gout; 49 [2.0%] treated with ULT). At BL, pts with HU were mostly male (76.0% vs 34.2%) and had a higher body mass index (30.9 vs 28.3 kg/m2) with more comorbidities, such as hypertension (43.8% vs 31.3%), compared to pts without HU. A higher proportion of pts with HU had dactylitis (34.5% vs 25.9%), and PsO (48.3% vs 36.3%) with a greater mean PASI score (13.6 vs 10.2), compared to pts without HU (Table 1). The proportion of pts achieving ACR50, resolution of enthesitis/dactylitis, and mean change in HAQ-DI score were comparable up to Week 52 irrespective of BL HU status. The PASI90 response rate was higher in pts without HU with SEC 150 mg (with and without load) and similar in SEC 300 mg group irrespective of BL HU status (Figure 1).Table 1.Demographics and baseline characteristicsParameters, mean ± SD unless specifiedWith hyperuricemia (N=822)Without hyperuricemia (N=1682)Age (Years)48.5 ± 12.4148.3 ± 12.19Gender (Male), n (%)625 (76.0)576 (34.2)Weight (kg)92.71 ± 18.6279.59 ± 17.55BMI (kg/m2)30.90 ± 5.8628.33 ± 5.91History of hypertension, n (%)360 (43.8)526 (31.3)History of diabetes mellitus, n (%)85 (10.3)144 (8.6)TJC20.6 ± 15.5221.3 ± 16.25SJC10.9 ± 9.3110.8 ± 9.13Enthesitis, n (%)412 (50.1)852 (50.7)Dactylitis, n (%)284 (34.5)436 (25.9)Evidence of current psoriasis; n (%)397 (48.3)611 (36.3)Mean PASI score*13.61 ± 11.0310.16 ± 9.13TNFi naїve, n (%)477 (58.0)938 (55.8)MTX use at randomization, n (%)321 (39.1)685 (40.7)Serum uric acid (µmol/L)420.7 ± 57.11274.9 ± 51.98CRP (mg/L)11.6 ± 18.6610.7 ± 23.36*not collected in MAXMISEBMI, body mass index; CRP, C-reactive protein; MTX, methotrexate; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitorConclusionIn this pooled analysis of SEC PsA studies, pts with HU reported a higher prevalence of hypertension, with more clinical dactylitis, and more PsO, with higher PASI score compared to pts without HU. Efficacy across all musculoskeletal manifestations was similar with SEC 150 and 300 mg; while PASI90 response rate was slightly better in patients without HU with SEC 150 mg, and similar with SEC 300 mg irrespective of HU status, at 1-year.References[1]Tripolino C, et al. Front Med. 2021;8:737573[2]AlJohani R, et al. J Rheumatol. 2018;45(2):213–7[3]Felten R, et al. Clin Rheumatol. 2020;39:1405–13[4]Widawski L, et al. Clin Rheumatol. 2022. https://doi.org/10.1007/s10067-022-06061-xDisclosure of InterestsRenaud FELTEN Consultant of: Novartis (Advisory board), Laura Widawski: None declared, Lionel Spielmann: None declared, Corine Gaillez Shareholder of: Novartis, Employee of: Novartis, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Jacques-Eric Gottenberg Consultant of: Novartis (Advisory board), Pierre-Marie Duret: None declared, Laurent Messer: None declared
Collapse
|
7
|
Feng X, Bao W, Wang X, Rao Q, Shi QL, Yue Z. [Pituicytoma: a clinicopathological analysis of twenty-one cases]. Zhonghua Bing Li Xue Za Zhi 2022; 51:314-318. [PMID: 35359042 DOI: 10.3760/cma.j.cn112151-20210818-00579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the clinicopathological features and treatment strategies of pituicytoma. Methods: Twenty-one cases of pituicytoma were collected at the First Affiliated Hospital of Nanjing Medical University and Jinling Hospital, Nanjing, China from 2009 to 2020. The clinical data of 21 pituicytoma patients was retrospectively analyzed, and the relevant literature was reviewed. Results: Twenty-one patients aged 4 to 68 years, including 8 males and 13 females. All patients underwent surgical treatment. Histologically, the tumor was consisted almost entirely of elongate, bipolar spindle cells arranged in a fascicular or storiform pattern. Mitotic figures were rare. Immunohistochemically, tumor cells were diffusely positive for S-100 protein (21/21), vimentin (15/15) and TTF1 (14/14), while they were weakly or focally positive for GFAP (13/16) and EMA (6/12). CKpan was negative in all cases and Ki-67 proliferation index was low (<5%). Among the 18 patients with follow-up, all survived and 2 relapsed after surgery. Conclusions: Pituicytoma is a rare low-grade glioma of the sellar area. It is easily confused with other sellar tumors. Preoperative diagnosis is difficult. It needs to be confirmed by histopathology and immunohistochemistry. Microsurgery is the main treatment method at present.
Collapse
Affiliation(s)
- X Feng
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - W Bao
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - X Wang
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - Q Rao
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - Q L Shi
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - Z Yue
- Department of Neurosurgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| |
Collapse
|
8
|
Fallon M, Sopata M, Dragon E, Brown M, Viktrup L, West C, Hamlett K, Bao W, Agyemang A. LBA62 Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Coates LC, Mease PJ, Gladman DD, Navarra S, Bao W, Gaillez C. POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Disease Activity Index for Psoriatic Arthritis (DAPSA) or the minimal disease activity (MDA) are considered for defining remission (REM) or low disease activity (LDA) in secukinumab (SEC) treated patients (pts) with PsA (Psoriatic Arthritis).1 Currently, limited SEC data are available on pts with PsA achieving sustained REM in clinical trials or real-world evidence, using these stringent criteria.Objectives:To report an exploratory analysis on achievement of sustained REM/LDA in pts with PsA treated with SEC and impact on structural outcomes, physical function and health-related quality of life (HRQoL) in the FUTURE 5 study (NCT02404350).Methods:FUTURE 5 is a randomised, double-blind, placebo-controlled 2-year phase 3 trial in pts with active PsA.2 Pts randomised to SEC 150 mg could be escalated to 300 mg from Week (Wk) 52 to 104, based on investigators’ judgement. The pts were categorised as either not achieving REM/LDA, achieving it once only or sustained REM/LDA, which was defined as pts who achieved REM/LDA between Wks 24-52 and maintained the same response at least 2 of the next 6 visits (visit every 8 Wks). Of pts who did not achieve REM/LDA, achieved REM/LDA (VLDA, DAPSA REM, MDA, DAPSA LDA+REM) between Wk 24 and 52, the relationship between absence of REM/LDA, REM/LDA, sustained REM/LDA, proportion of pts with non-radiographic progression (assessed using the van der Heijde [mTSS]), physical function (health assessment questionnaire disability index [HAQ-DI]), and short form-36 physical component score [SF-36 PCS])3 were assessed.Results:In total, 996 pts were randomised to one of 4 treatment groups: SEC 300 mg loading dose (LD; N=222), SEC 150 mg LD (N=220), SEC 150 mg no loading dose (NL; N=222), and placebo (N=332). The baseline clinical characteristics were comparable across treatment groups. Majority of pts could achieve either sustained MDA/sustained DAPSA LDA+REM (Figure 1). Pts achieving REM/LDA, whether at one visit or consistently, showed improved physical function and SF36-PCS at Wk 104.3A high proportion of pts did not show radiographic progression at Wk 104 irrespective of achievement of REM/LDA category (Table 1).Conclusion:The majority of patients treated with secukinumab were able to achieve sustained LDA. Sustained LDA/REM was associated with improved HRQoL, physical function and inhibition of structural damage progression.References:[1]Coates LC, et al. J Rheumatol. 2018;46(1):38–42.[2]Van der Heijde D, et al. Rheumatology. 2020;59(6):1325–1334.[3]Coates L, et al. [0353]. Arthritis Rheumatol. 2020;72 (suppl 10).Figure 1.Proportion of patients achieving VLDA/MDA/DAPSA REM/DAPSA REM+LDASus-tained REM/LDA was defined if the same response was achieved at least 2 out of the next 6 visits (every 8 weeks), respectively. DAPSA, Disease activity in Psoriatic Arthritis; LD, loading dose; LDA, Low Disease Activity; MDA, Minimal Disease Activity; N, number of randomised patients assessed at both Week 24 and 104; NL, without loading dose; REM, remission; SEC, secukinumab; VLDA, Very Low Disease ActivityTable 1.Percentage of vdH-mTSS no progression at Week 104 (change from baseline ≤0.5) by REM/LDA and sustained REM/LDA statusREM and LDA composite indices, n (%)Treatment groupNo REM/LDAREM/LDA only onceSustained REM/LDAMDASEC 150 mg LD64 (75.3)16 (80.0)76 (86.4)SEC 150 mg NL56 (75.7)15 (78.9)69 (82.1)SEC 300 mg LD58 (79.5)19 (95.0)100 (94.3)VLDASEC 150 mg LD108 (78.8)15 (83.3)30 (88.2)SEC 150 mg NL95 (75.4)13 (81.3)32 (91.4)SEC 300 mg LD 115 (84.6)17 (94.4)45 (100.0)DAPSA REMSEC 150 mg LD77 (76.2)11 (78.6)46 (92.0)SEC 150 mg NL65 (71.4)10 (76.9)50 (87.7)SEC 300 mg LD82 (83.7)14 (93.3)63 (96.9)DAPSA LDA + REMSEC 150 mg LD29 (70.7)16 (84.2)80 (84.2)SEC 150 mg NL23 (71.9)15 (75.0)79 (79.0)SEC 300 mg LD39 (88.6)21 (84.0)97 (89.0)Sustained REM/LDA was defined if the same response was achieved at least twice out of the next 6 visits (every 8 weeks), respectively. n, number of evaluable patients; vdH-mTSS, van der Heijde- modified total Sharp scoreDisclosure of Interests:Laura C Coates Consultant of: Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Celgene, Lilly, Novartis and Pfizer, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, BMS, Boehringer Ingelheim, Galapagos, Celgene, Genentech, Gilead, Janssen, Lilly, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, SUN, and UCB, Dafna D Gladman Consultant of: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Sandra Navarra Speakers bureau: Pfizer, Novartis, Astra-Zeneca, Janssen, Lilly, and Astellas, Consultant of: Pfizer, Novartis, Astra-Zeneca, Janssen, Lilly, and Astellas, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis.
Collapse
|
10
|
Goupille P, Behrens F, Coates LC, Gratacos-Masmitja J, Mease PJ, Gladman DD, Nash P, Kavanaugh A, Martin R, Bao W, Gaillez C, Mcinnes I. POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:EXCEED (NCT02745080) was the first fully blinded head-to-head trial to evaluate the efficacy and safety of secukinumab (SEC) versus (vs) adalimumab (ADA) monotherapy in patients with active psoriatic arthritis (PsA) with a primary endpoint of American College of Rheumatology (ACR) 20 at Week 52. Although SEC narrowly missed statistical significance for superiority vs ADA, numerically higher response for other musculoskeletal endpoints and composite indices were observed with SEC.1Objectives:To explore the effect of SEC and ADA on ACR core components, function and Health-related Quality of Life (HRQoL) outcomes.Methods:Patients were randomised 1:1 to receive SEC 300 mg (N=426) subcutaneous (s.c.) at baseline, Week 1-4, followed by every 4 weeks until Week 48 or ADA 40 mg (N=427) s.c. at baseline followed by same dosing every 2 weeks until Week 50. The primary, key secondary and some exploratory endpoints at Week 52 were previously reported.1 A supportive analysis for ACR50 response using logistic regression model and trimmed means model for Health Assessment Questionnaire-Disability Index (HAQ-DI) with gender and smoking status as factors was performed to adjust for imbalances in baseline characteristics. An exploratory analysis of ACR core components with SEC vs ADA at Week 52 was conducted using a mixed-effects repeated measures model that included tender and swollen joint counts, patient and physician global assessment, PsA pain (VAS) and erythrocyte sedimentation rate. HRQoL variables were also exploratory and assessed based on Short Form Health Survey Physical/Mental Component Summary (SF-36 PCS/MCS) scores and Dermatology Life Quality Index (DLQI).Results:The demographic and baseline disease characteristics were comparable across treatment groups, except for an imbalance in sex (females: 51.2% vs 46.4%) and smoking status (yes: 21.8% vs 17.8%) in SEC and ADA group, respectively. At Week 52, ACR50 responses were 49.0% and 44.8% (P=0.0929) and HAQ-DI mean change from baseline were −0.69 and −0.58 (P=0.0314) in SEC and ADA treatment groups, respectively after adjusting for gender and smoking status. No major difference across ACR core components was observed in both treatment groups at Week 52 (Table 1). At Week 52, SEC presented similar improvement in SF-36 PCS/MCS score and numerically higher improvement in DLQI compared to ADA (Figure 1).Conclusion:Secukinumab provided similar improvements in ACR core components and SF-36 based quality of life at Week 52 with adalimumab. Greater improvement in HAQ-DI response and DLQI was demonstrated with secukinumab compared to adalimumab.References:[1]McInnes IB, et al. Lancet. 2020; 395:1496–505.Table 1.ACR Core Components at Week 52VariablesSecukinumab 300 mg(N=426)Adalimumab 40 mg(N=427)P-valueBL, mean ± SELSM change from BL ± SEBL, mean ± SELSM change from BL ± SETender joint score(based on 78 joints)19.4 ± 13.86−14.27 ± 0.4420.6 ± 14.81−13.90 ± 0.450.5549Swollen joint score(based on 76 joints)9.7 ± 7.30−8.41 ± 0.1910.2 ± 7.86−8.06 ± 0.200.1962Patients global assessment64.0 ± 19.67−33.81 ± 1.1461.9 ± 20.75−31.61 ± 1.190.1825Physicians global assessment60.0 ± 17.12−46.24 ± 0.8061.4 ± 15.92−43.63 ± 0.840.0243Psoriatic arthritis pain (VAS)58.6 ± 23.49−30.21 ± 1.1857.9 ± 22.42−29.44 ± 1.230.6500Erythrocyte sedimentation rate (mm/h)23.8 ± 18.93−9.63 ± 0.6223.9 ± 17.99−9.28 ± 0.640.7029LS mean and nominal P-values are from a mixed-effects repeated measures model with treatment group, analysis visit as factors, weight and BL score as covariates, and by treatment and BL score as interaction terms, unstructured covariance structure. ACR, American College of Rheumatology; BL, baseline; LSM, least squares mean; N, total number of randomised patients; SE, standard error; VAS, visual analogue scaleFigure 1.HRQoL Analysis at Week 52Disclosure of Interests:Philippe Goupille Speakers bureau: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Grant/research support from: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Frank Behrens Paid instructor for: Eli Lilly, Consultant of: Pfizer, AbbVie, Sanofi, Eli Lilly, Novartis, Genzyme, Boehringer Ingelheim, Janssen, MSD, Celgene, Roche and Chugai, Grant/research support from: Pfizer, Janssen, Chugai, Celgene and Roche, Laura C Coates Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Biogen, BMS, Celgene, Domain, Eli Lilly, Gilead, GSK, Janssen, Medac, Novartis, Pfizer, Serac and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Jordi Gratacos-Masmitja Speakers bureau: AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Novartis and Pfizer, Consultant of: AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Novartis and Pfizer, Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Novartis and Pfizer, Philip J Mease Speakers bureau: AbbVie, Amgen, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Galapagos, Celgene, Genentech, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Genentech, Gilead, Janssen, Eli Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB, Dafna D Gladman Consultant of: Amgen, AbbVie, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Grant/research support from: Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Peter Nash Speakers bureau: Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, Celgene, UCB, Eli Lilly, MSD, Sanofi, Gilead, Consultant of: Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, Celgene, UCB, Eli Lilly, MSD, Sanofi, Gilead, Grant/research support from: Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, Celgene, UCB, Eli Lilly, MSD, Sanofi, Gilead, Arthur Kavanaugh Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, and UCB, Ruvie Martin Shareholder of: Novartis, Employee of: Novartis, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis, Iain McInnes Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB.
Collapse
|
11
|
Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol 2021; 185:1124-1134. [PMID: 33913511 PMCID: PMC9291158 DOI: 10.1111/bjd.20413] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2021] [Indexed: 11/28/2022]
Abstract
Background Secukinumab [an interleukin (IL)‐17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL‐12/23 inhibitor) in patients with moderate‐to‐severe plaque psoriasis. Objectives To report 52‐week results from a prespecified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate‐to‐severe plaque psoriasis from the head‐to‐head EXCEED monotherapy study comparing secukinumab with adalimumab. Methods Patients were randomized to receive secukinumab 300 mg via subcutaneous injection at baseline, week 1–4, and then every 4 weeks until week 48 or adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50. Assessments in patients with concomitant moderate‐to‐severe psoriasis, defined as having affected body surface area > 10% or Psoriasis Area and Severity Index (PASI) ≥ 10 at baseline, included musculoskeletal, skin and quality‐of‐life outcomes. Missing data were handled using multiple imputation. Results Of the 853 patients [secukinumab (N = 426), adalimumab (N = 427)], 211 (24·7%) had concomitant moderate‐to‐severe psoriasis [secukinumab (N = 110, 25·8%), adalimumab (N = 101, 23·7%)]. Up to week 50, 5·5% of patients discontinued secukinumab vs.17·8% in the adalimumab group. The proportion of patients who achieved American College of Rheumatology (ACR) 20 response was 76·4% with secukinumab vs. 68·3% with adalimumab (P = 0·175), PASI 100 response was 39·1% vs. 23·8% (P = 0·013), and simultaneous improvement in ACR 50 and PASI 100 response at week 52 was 28·2% vs. 17·7%, respectively (P = 0·06). Secukinumab demonstrated consistently higher responses vs. adalimumab across skin endpoints. Conclusions This prespecified analysis in PsA patients with concomitant moderate‐to‐severe plaque psoriasis in the EXCEED study provides further evidence that IL‐17 inhibitors offer a comprehensive biological treatment to manage the concomitant features of psoriasis and PsA.
What is already known about this topic?
Secukinumab, an interleukin‐17A inhibitor, has previously been reported to have significantly higher efficacy in head‐to‐head trials vs. etanercept and ustekinumab in patients with moderate‐to‐severe plaque psoriasis.
What does this study add?The results of the study provide valuable head‐to‐head data on the efficacy of two biologics with different mechanisms of action (secukinumab and adalimumab) as first‐line biological monotherapy for patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis. The findings of this study can further help physicians to make informed and evidence‐based decisions for the treatment of patients with active psoriatic arthritis who have concomitant moderate‐to‐severe plaque psoriasis.
Linked Comment: E. Sbidian and L. Pina‐Vegas. Br J Dermatol 2021; 185:1085.
Collapse
Affiliation(s)
- A B Gottlieb
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J F Merola
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - K Reich
- Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg- Eppendorf, Hamburg, Germany
| | - F Behrens
- Rheumatology University Hospital and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP and Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Goethe University, Frankfurt, Germany
| | - P Nash
- Department of Medicine, Griffith University, Brisbane, QLD, Australia
| | - C E M Griffiths
- The Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK
| | - W Bao
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - P Pellet
- Novartis Pharma AG, Basel, Switzerland
| | - L Pricop
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | |
Collapse
|
12
|
Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 2021; 185:935-944. [PMID: 33829482 DOI: 10.1111/bjd.20136] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies. OBJECTIVES To assess the malignancy risk in patients with secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). METHODS This integrated safety analysis from both the secukinumab clinical trial programme and postmarketing safety surveillance data included any patient receiving at least one approved dose of secukinumab with a maximum of 5 years of follow-up. Safety analyses evaluated the rate of malignancy using exposure-adjusted incidence rates [EAIR; incidence rates per 100 patient treatment-years (PTY)]. Standardized incidence ratios (SIRs) were reported using the Surveillance, Epidemiology, and End Results Program (SEER) database as a reference population. Crude incidence of malignancy was also reported using postmarketing surveillance data. RESULTS Safety data from 49 clinical trials with secukinumab-treated patients were included: 10 685 patients with psoriasis, 2523 with PsA and 1311 with AS. Across indications over a 5-year period, the EAIR of malignancy was 0·85 per 100 PTY [95% confidence interval (CI) 0·74-0·98] in secukinumab-treated patients, corresponding to 204 patients per 23 908 PTY. Overall, the observed vs. expected number of malignancies from secukinumab clinical trial data were comparable, as indicated by an SIR of 0·99 (95% CI 0·82-1·19) across indications. The estimated crude cumulative incidence reporting rate per 100 PTY for malignancy was 0·27 in the postmarketing surveillance data across indications with a cumulative exposure of 285 811 PTY. CONCLUSIONS In this large safety analysis, the risk of malignancy was low for up to 5 years of secukinumab treatment. These data support the long-term use of secukinumab in these indications.
Collapse
Affiliation(s)
- M Lebwohl
- Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - A Deodhar
- Oregon Health & Science University, Portland, OR, USA
| | - C E M Griffiths
- The Dermatology Centre, The University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK
| | - M A Menter
- Division of Dermatology, Baylor Scott & White Health, Dallas, TX, USA
| | - D Poddubnyy
- Division of Gastroenterology, Infectious Diseases and Rheumatology, Charité, Universitätsmedizin Berlin, Germany, and Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
| | - W Bao
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - V Jehl
- Novartis Pharma AG, Basel, Switzerland
| | - K Marfo
- Novartis Pharma AG, Basel, Switzerland
| | | | - A Shete
- Novartis Pharma AG, Basel, Switzerland
| | - V Trivedi
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - P J Mease
- Department of Rheumatology, Swedish Health Services/Providence St Joseph Health and University of Washington, Seattle, WA, USA
| |
Collapse
|
13
|
Wang XX, Wei X, Wang X, Ma HH, Rao Q, Bao W. [Pancreatic hamartoma: report of a case]. Zhonghua Bing Li Xue Za Zhi 2020; 49:847-849. [PMID: 32746557 DOI: 10.3760/cma.j.cn112151-20191127-00761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- X X Wang
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - X Wei
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - X Wang
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - H H Ma
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - Q Rao
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - W Bao
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| |
Collapse
|
14
|
Deodhar A, Mcinnes I, Baraliakos X, Reich K, Gottlieb AB, Lebwohl M, Schreiber S, Bao W, Marfo K, Richards H, Pricop L, Shete A, Safi J, Mease PJ. FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Pooled safety data has been reported with secukinumab (SEC) in patients (pts) with Psoriatic arthritis (PsA), Ankylosing Spondylitis (AS) and Psoriasis (PsO).1Objectives:To report longer-term safety data of SEC treatment in PsA, AS, PsO pts up to 5 years.Methods:The integrated clinical trial safety dataset included data pooled from 28 randomised controlled clinical trials of SEC 300 or 150 or 75 mg in PsO (11 Phase 3 and 8 Phase 4 trials), PsA (5 Phase 3 trials), and AS (4 Phase 3 trials), along with post-marketing safety surveillance data with a cut-off date of 25 December 2018. Adverse events (AEs) were reported as exposure-adjusted incident rates (EAIRs) per 100 pt-years. Analyses included all pts who received ≥1 dose of SEC.Results:A total of 12637 pts (8819, 2678 and 1140 pts with PsO, PsA and AS, with an exposure of 15063.1, 5984.6 and 3527.2 pt-years, respectively) were included. The most frequent AE was upper respiratory tract infection and EAIR per 100 pt-years for IBD, malignancies and MACE remained low. The EAIR per 100 pt-years for adverse events (AEs) of special interest are reported in Table 1. The cumulative post-marketing exposure to SEC was estimated to be ~285,811 pt-years across the approved indications. Safety data from post-marketing surveillance are reported in Table 2.Table 1.Selected AEs of interest with SEC across pooled clinical trialsVariablePsOPsAASSECN=8819SECN=2678SECN=1140Exposure (Days), Mean (SD)623.9 (567.7)816.2 (580.7)1130.1 (583.0)Death, n (%)15 (0.2)13 (0.5)10 (0.9)Selected AE’s of interest, EAIR (95% CI)Serious infections11.4 (1.2, 1.6)1.8 (1.5, 2.2)1.2 (0.9, 1.6)Candidainfections22.9 (2.7, 3.2)1.5 (1.2, 1.9)0.7 (0.5, 1.1)IBD3Crohn’s disease3Ulcerative colitis30.01 (0.0, 0.05)0.1 (0.05, 0.2)0.1 (0.08, 0.2)0.03 (0.0, 0.1)0.1 (0.04, 0.2)0.1 (0.04, 0.2)0.03 (0.0, 0.2)0.4 (0.24, 0.7)0.2 (0.1, 0.5)MACE40.4 (0.31, 0.5)0.4 (0.3, 0.6)0.7 (0.4, 1.0)Uveitis30.01 (0.0, 0.05)0.1 (0.04, 0.2)1.2 (0.9, 1.7)Malignancy50.9 (0.7, 1.0)1.0 (0.77, 1.3)0.5 (0.3, 0.8)1Rates for system organ class;2Rates for high level term;3Rates for preferred term (PT; IBD for unspecified IBD);4Rates for Novartis MedDRA Query term;5Rates for standardized MedDRA query term – ‘malignancies and unspecified tumour’; EAIR, exposure adjusted incidence rate per 100 pt-years; N, number of pts in the analysisTable 2.Summary of SEC post-marketing safetyExposure (PTY)PSUR126Dec14 -25Jun15PSUR226 Jun - 25Dec15PSUR326Dec15 -25Jun16PSUR426Jun -25Dec16PSUR526Dec16 -25Dec17PSUR626Dec17 -25Dec18Cumulative18387450168712854993744137325285811 n (Reporting rate PTY)Serious infections89 (4.8)149 (2.0)232 (1.4)475 (1.7)649 (0.7)1841 (1.3)3980 (1.4)Malignancy2 (0.1)15 (0.2)21 (0.1)50 (0.2)225 (0.2)422 (0.3)788 (0.3)Total IBD4 (0.2)12 (0.2)37(0.2)46 (0.2)185 (0.2)340 (0.3)693 (0.2)MACE6 (0.3)15 (0.2)16 (0.1)39 (0.1)151 (0.2)238 (0.2)504 (0.2)PSUR, periodic safety update report; PTY, pt-treatment yearsConclusion:In this long-term analysis across clinical trials and post-marketing surveillance, of pts with PsO, PsA and AS, SEC was well tolerated, with a safety profile consistent with previous reports.1Reference:[1]Deodhar et al. Arthritis Research & Therapy (2019) 21:111.Disclosure of Interests:Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Kristian Reich Grant/research support from: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Consultant of: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Speakers bureau: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Mark Lebwohl Grant/research support from: AbbVie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, LLC, Kadmon Corp., LLC, Leo Pharmaceutucals, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc., and ViDac, Consultant of: Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica, Stefan Schreiber Consultant of: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist and Falk, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Kwaku Marfo Shareholder of: Novartis, Employee of: Novartis, Hanno Richards Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Abhijit Shete Shareholder of: Novartis, Employee of: Novartis, Jorge Safi Shareholder of: Novartis, Employee of: Novartis, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau
Collapse
|
15
|
Yang L, Feng H, Liu Y, Liu Z, Wang S, Dong L, Huo Y, Bao W. Influence of bamboo vinegar powder supplementation on growth performance, apparent digestibility and expression of growth-related genes in finishing pigs. ANIM NUTR FEED TECHN 2020. [DOI: 10.5958/0974-181x.2020.00017.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
16
|
Pascual-Figal D, Bao W, Senni M, Wachter R, Behlolavek J, Chakrabarti A, Noe A, Schwende H, Butylin D, Prescott M. 1410Clinical predictors of NT-proBNP response to early initiation of sacubitril/valsartan after hospitalisation for decompensated heart failure: An analysis of the TRANSITION study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
NT-proBNP has diagnostic and prognostic value in patients with heart failure (HF). Compared with enalapril, sacubitril/valsartan (S/V) significantly reduced NT-proBNP within 1 week (wk) of administration and reduced HF re-hospitalisation in patients with acute decompensated HF (ADHF) in PIONEER-HF. Identification of predictors of NT-proBNP reduction with S/V could aid prognostication following hospitalisation.
Methods
TRANSITION (NCT02661217) is an open label study in stabilised ADHF patients with HFrEF that compared S/V initiation pre- versus post-discharge (within 2 wk of discharge). Baseline NT-proBNP was measured at randomisation in both S/V groups (n=950). Clinical predictors of favourable response of NT-proBNP to S/V therapy (defined as reduction to <1000 pg/ml or >30% reduction vs. baseline) were studied at discharge, 4 wk and 10 wk post-randomisation.
Results
Median NT-proBNP at randomisation was similar in patients with S/V started pre- and post-discharge (1919 vs 1659 pg/ml). In patients receiving S/V in-hospital, NT-proBNP was reduced by 28% at discharge, compared to a 3% reduction in patients receiving optimised standard of care (between group p<0.001). A favorable response was reached in 46% vs 18% patients at discharge, 46% vs 42% at 4 weeks and 51% vs 48% at 10 weeks in pre- vs post-discharge groups. (Figure 1). Predictors of favourable NT-proBNP response to S/V at discharge were hypertension and shorter time from admission to first S/V dose. At 4 wk after randomisation, NT-proBNP was reduced similarly in patients started on S/V pre- and post-discharge. When the two S/V initiation groups were combined, predictors of favorable NT-proBNP response at 4 wk were higher initial dose of S/V (≥49/51 mg b.i.d.), higher baseline levels of NT-proBNP, de novo HF hospitalisation, ACEI/ARB naïve, lower baseline creatinine, no atrial fibrillation (AFib), no prior myocardial infarction (MI). A further reduction in NT-proBNP was seen at 10 wk post-randomisation in patients started on S/V pre- and post-discharge (38% vs 34%, between group p=0.250). Predictors of favourable NT-proBNP response to S/V were similar at 4 wk and 10 wk post-randomisation.
Conclusion
In-hospital initiation of sacubitril/valsartan shortly after stabilisation was associated with a prompt improvement of NT-proBNP already at discharge, whereas higher baseline levels of NT-proBNP, higher starting dose, absence of AFib and MI history, de novo HF and ACEI/ARB naïve status were associated with favourable NT-proBNP response in the vulnerable phase after discharge.
Acknowledgement/Funding
The TRANSITION study was funded by Novartis
Collapse
Affiliation(s)
| | - W Bao
- Novartis Pharmaceuticals, East Hanover, United States of America
| | - M Senni
- Ospedale Papa Giovanni XXIII, Heart Failure and Transplant Unit, Bergamo, Italy
| | - R Wachter
- Leipzig University Hospital, Leipzig, Germany
| | | | | | - A Noe
- Novartis Pharma AG, Basel, Switzerland
| | | | - D Butylin
- Novartis Pharma AG, Basel, Switzerland
| | - M Prescott
- Novartis Pharmaceuticals, East Hanover, United States of America
| |
Collapse
|
17
|
Wachter R, Pascual-Figal D, Belohlavek J, Straburzynska-Migaj E, Witte KK, Fonseca C, Cavusoglu Y, Pouleur AC, Goncalvesova E, Lonn E, Noe A, Schwende H, Bao W, Butylin D, Senni M. P773Initiation of sacubitril/valsartan and optimisation of evidence-based heart failure therapies after hospitalisation for acute decompensated heart failure: An analysis of the TRANSITION study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Optimisation of chronic heart failure (HF) therapy remains the key strategy to improve outcomes after hospitalisation for acute decompensated HF (ADHF) with reduced ejection fraction (HFrEF). Initiation and uptitration of disease-modifying therapies is challenging in this vulnerable patient population. We aimed to describe the patterns of treatment optimisation including sacubitril/valsartan (S/V) in the TRANSITION study.
Methods
TRANSITION (NCT02661217) was a randomised, open-label study comparing S/V initiation pre- vs. post-discharge (1–14 days) in patients admitted for ADHF after haemodynamic stabilisation. The primary endpoint was the proportion of patients achieving 97/103 mg S/V twice daily (bid) at 10 weeks post-randomisation. Up-titration of S/V was as per label. Information on dose of S/V and on the use of concomitant HF medication was collected at each study visit up to week 26.
Results
A total of 493 patients received at least one dose of S/V in the pre-discharge arm and 489 patients in the post-discharge arm. One month after randomisation, 45% of patients in the pre-d/c arm vs. 44% in the post-discharge arm used 24/26 mg bid starting dose and 42% vs. 40% were on 49/51 mg S/V bid, respectively. At week 10, 47% of patients had achieved the target dose in the pre-discharge arm vs. 51% in the post-discharge arm. At the end of the follow-up at 26 weeks, the proportion of patients on S/V target dose further increased to 53% in the pre-discharge and 61% in the post-discharge arm (Figure 1). At week 10, the mean dose of S/V was 132 mg in the pre-discharge arm and 136 mg in the post-discharge arm, and at week 26, it was 140 mg and 147 mg, respectively.
Before hospital admission, 52% and 54% of the patients received a beta-blocker (BB) in the pre-discharge and post-discharge group, respectively, and 42% in both arms received a mineralcorticoid receptor antagonist (MRA). At time of discharge, 68% and 71%% of the patients received a BB and 68% and 65% an MRA, in the pre-discharge and post-discharge groups, respectively. These proportions remained stable to week 10 and week 26.
Uptitration of sacubitril/valsartan
Conclusions
In the vulnerable post-ADHF population, initiation of S/V and up-titration to target dose was feasible within 10 weeks in half of the patients alongside with a 20% increase in the use of other disease-modifying medications that remained stable through the end of the 6-month follow-up.
Acknowledgement/Funding
The TRANSITION study was funded by Novartis
Collapse
Affiliation(s)
- R Wachter
- Leipzig University Hospital, Leipzig, Germany
| | | | | | | | - K K Witte
- University of Leeds, Leeds, United Kingdom
| | - C Fonseca
- Hospital de Sao Francisco Xavier, Lisbon, Portugal
| | - Y Cavusoglu
- Eskisehir Osmangazi University, Eskisehir, Turkey
| | | | - E Goncalvesova
- The National Institute of Cardiovascular Diseases, Bratislava 37, Slovakia
| | - E Lonn
- Hamilton Health Sciences General Site, Hamilton, Canada
| | - A Noe
- Novartis Pharma AG, Basel, Switzerland
| | | | - W Bao
- Novartis Pharmaceuticals, East Hanover, United States of America
| | - D Butylin
- Novartis Pharma AG, Basel, Switzerland
| | - M Senni
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
18
|
Pascual-Figal D, Witte KK, Wachter R, Belohlavek J, Straburzynska-Migaj E, Fonseca C, Cavusoglu Y, Pouleur AC, Mueller C, Lonn E, Noe A, Schwende H, Bao W, Butylin D, Senni M. P1637Rehospitalisations during 26 weeks of follow up from initiation of sacubitril/valsartan after acute decompensated heart failure: An analysis of the TRANSITION study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Patients with acute decompensated heart failure (ADHF) are at high risk of recurrent hospitalisations and death. In-hospital initiation of sacubitril/valsartan (S/V) reduced the risk for HF re-hospitalisation by 44% compared to enalapril in the PIONEER-HF study during the 8-week follow-up period. We aimed to describe the pattern of readmissions and their causes in the TRANSITION study, which randomised participants to pre-discharge or post-discharge initation of S/V.
Methods
TRANSITION (NCT02661217) was a randomised, open-label study comparing S/V initiation pre- vs. post-discharge (1–14 days) in haemodynamically stabilised patients with HF with reduced ejection fraction, admitted for ADHF. The primary endpoint was the proportion of patients achieving 97/103 mg S/V twice daily at 10 weeks post-randomisation. Information on rehospitalisation was collected throughout the study up to 26 weeks.
Results
A total of 493 patients received S/V in the pre-discharge arm and 489 patients in the post-discharge arm. Readmissions due to any cause were reported in 9.7% and 18.1% in the pre-discharge arm vs. 10.6% and 21.3% in the post-discharge arm within 30 days, and 10 weeks respectively. During the 26-weeks follow-up, all-cause readmission was reported in 34.5% of patients in the pre-discharge arm vs. 34.6% in the post-discharge arm. Median time to first rehospitalisation was 67 days in the pre-discharge arm (IQR: 26–110 days) and 50 days (IQR: 23–108 days) in the post-discharge arm. At least one HF hospitalisation was reported in 7.5% of patients in the pre-discharge arm and 7.4% in the post-discharge arm during 10 weeks and in 11.8% and 12.3% of patients, respectively, during 26 weeks of follow-up. Median duration of HF readmission was 7 days (IQR: 4–11 days) in the pre-discharge group and 6.5 days (IQR: 6.5–10 days) in the post-discharge arm. In total 2.6% and 5.5% patients in pre-discharge arm and 3.9% and 7% in the post-discharge arm visited an emergency room during 10 weeks and 26 weeks, respectively.
Conclusions
Initiation of S/V in patients hospitalised for ADHF either before or shortly after discharge, results in comparable rates of all cause and HF rehospitalisations, as well as emergency room visits without hospital admission over the 26 week follow-up period. HF re-hospitalisations rates at 10 weeks in TRANSITION are in line with the 8% in S/V arm reported in PIONEER-HF during the 8-weeks follow-up.
Acknowledgement/Funding
The TRANSITION study was funded by Novartis
Collapse
Affiliation(s)
| | - K K Witte
- University of Leeds, Leeds, United Kingdom
| | - R Wachter
- Leipzig University Hospital, Leipzig, Germany
| | | | | | - C Fonseca
- Hospital de Sao Francisco Xavier, Lisbon, Portugal
| | - Y Cavusoglu
- Eskisehir Osmangazi University, Eskisehir, Turkey
| | | | - C Mueller
- University Hospital Basel, Basel, Switzerland
| | - E Lonn
- Hamilton Health Sciences, Hamilton, Canada
| | - A Noe
- Novartis Pharma AG, Basel, Switzerland
| | | | - W Bao
- Novartis Pharmaceuticals, East Hanover, United States of America
| | - D Butylin
- Novartis Pharma AG, Basel, Switzerland
| | - M Senni
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
19
|
Shi Y, Bo Z, Pang G, Qu X, Bao W, Yang L, Ma Y. MiR-99a-5p regulates proliferation, migration and invasion abilities of human oral carcinoma cells by targeting NOX4. Neoplasma 2019; 64:666-673. [PMID: 28592118 DOI: 10.4149/neo_2017_503] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Previous research has showed that miR-99a-5p was a tumor suppressor. The aim of our study was to explore the effect of miR-99a-5p on the vitality and proliferation, migration together with the invasion of oral tumor cells via inhibiting the expression of NOX4. QRT-PCR and Western blot were applied to examine the expression level of miR-99a-5p and NOX4 in human oral tumorous and adjacent tissues. Dual luciferase reporter gene assay was applied to confirm that miR-99a-5p negatively regulated directly on NOX4 in TSCC1 cells. Cell transfection and lentiviral vectors were used to up-regulate expression of miR-99a-5p and NOX4, respectively. Cell proliferation, cell cycle, apoptosis and invasion along with the migration in different groups were assessed using MTT assay, colony formation assay, the flow cytometry, transwell assay and the wound healing assay, respectively. MiR-99a-5p was under-expressed in human oral tumor, while NOX4 was over-expressed. There was a negative relationship between miR-99a-5p and NOX4. Up-regulating miR-99a-5p or down-regulating NOX4 suppressed the vitality, proliferation, migration together with invasion of TSCC1 cells. MiR-99a-5p affected the vitality and proliferation, migration together with the invasion of oral tumor cells through targeting NOX4.
Collapse
|
20
|
Tripathy D, Hortobagyi G, Chan A, Im SA, Chia S, Yardley D, Esteva FJ, Hurvitz S, Kong O, Bao W, Rodriguez Lorenc K, Diaz-Padilla I, Slamon DJ. Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In three separate Phase III randomized, placebo-controlled trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners prolonged progression-free survival (PFS) vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we further evaluate the efficacy of RIB-based regimens of interest (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) in pts who were ET-naïve in the ABC setting, using pooled data from three Phase III trials: MONALEESA (ML)-2 (NCT01958021; all pts), ML-3 (NCT02422615; no prior ET for ABC subgroup only), and ML-7 (NCT02278120; RIB + NSAI subgroup only).
Methods: Postmenopausal pts with no prior ET for ABC received RIB (600 mg/day; 3-weeks-on/1-week-off) or PBO + either letrozole (2.5 mg/day) in ML-2 or FUL (500 mg every 28 days, with an additional dose on Day 15 of Cycle 1) in ML-3. In ML-7, premenopausal pts with no prior ET and ≤1 line of chemotherapy for ABC received RIB or PBO + goserelin (3.6 mg every 28 days) + NSAI (anastrozole [1 mg/day]/letrozole [2.5 mg/day]). The primary endpoint of all three trials was locally assessed PFS. Secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DoR; ML-3 and -7). DoR was an exploratory endpoint in ML-2.
Results: Data were pooled for 820 pts treated with RIB + ET (ML-2: n=334; ML-3: n=238; ML-7: n=248) and 710 pts treated with PBO + ET (ML-2: n=334; ML-3: n=129; ML-7: n=247). As of the data cutoffs (ML-2: January 2, 2017; ML-3: November 3, 2017; ML-7: August 20, 2017), in the RIB + ET vs PBO + ET arms, 385 (47%) vs 234 (33%) pts remained on-treatment; the most common reason for discontinuation was disease progression (n=292 [36%] vs n=391 [55%]). In this pooled analysis, median PFS was prolonged for RIB + ET vs PBO + ET, with a hazard ratio of 0.570 (95% confidence interval [CI] 0.491–0.662); median PFS was 25.3 months (95% CI 23.9–29.6) vs 15.6 months (95% CI 14.4–16.9), respectively. Consistent PFS benefit for RIB + ET vs PBO + ET was observed across pt subgroups, including ECOG performance status, age, race, or presence/absence of liver and/or lung metastases or bone-only disease. Among all pts in the pooled analysis, the ORR was 41% for RIB + ET vs 28% for PBO + ET and the CBR was 79% vs 70%, respectively. In pts with measurable disease at baseline (RIB + ET: n=639; PBO + ET: n=542), the ORR was 51% for RIB + ET vs 37% for PBO + ET and the CBR was 79% vs 68%, respectively. In the RIB + ET vs PBO + ET arms, the median DoR was 26.7 months vs 20.0 months. A decrease in best percentage change from baseline in the sum of longest diameters per RECIST was observed in 86% of pts receiving RIB + ET vs 73% of pts receiving PBO + ET.
Conclusions: RIB in combination with various ET partners demonstrates improved clinical outcomes vs PBO + ET across a broad population of pts with HR+, HER2– ABC. These data provide further support for the use of RIB-based combinations in pre- and postmenopausal pts with HR+, HER2– ABC who have received no prior ET for advanced disease.
Citation Format: Tripathy D, Hortobagyi G, Chan A, Im S-A, Chia S, Yardley D, Esteva FJ, Hurvitz S, Kong O, Bao W, Rodriguez Lorenc K, Diaz-Padilla I, Slamon DJ. First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-05.
Collapse
Affiliation(s)
- D Tripathy
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - G Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - A Chan
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - S-A Im
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - S Chia
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - D Yardley
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - FJ Esteva
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - S Hurvitz
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - O Kong
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - W Bao
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - K Rodriguez Lorenc
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - I Diaz-Padilla
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - DJ Slamon
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| |
Collapse
|
21
|
Burris HA, Chan A, Im SA, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we further evaluate the safety of RIB-based regimens of interest for the proposed indication (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) using pooled data from three Phase III trials (MONALEESA [ML]-2 [NCT01958021], -3 [NCT02422615], and -7 [NCT02278120]).
Methods: Postmenopausal pts with HR+, HER2– ABC received RIB (600 mg/day; 3-weeks-on/1-week-off) or PBO + letrozole (LET; 2.5 mg/day; ML-2 [no prior ET for ABC]) or FUL (500 mg, Days 1 and 15 of Cycle 1, then Day 1 of every cycle thereafter; ML-3; no or ≤1 prior line of ET for ABC]). Premenopausal pts (ML-7; no prior ET and ≤1 chemotherapy for ABC]) received RIB or PBO + anastrozole (1 mg/day)/LET (2.5 mg/day) + goserelin (3.6 mg every 28 days). Adverse events (AEs) were characterized per Common Terminology Criteria for Adverse Events v4.03; safety analyses included time to first event, duration of event, and rate of associated RIB/PBO discontinuations.
Results: Data for 1883 pts were pooled; 1065 pts received RIB + ET and 818 pts received PBO + ET (median exposure to study treatment: 17 and 13 months, respectively). Exposure-adjusted incidence rates for AEs of special interest were 561 and 131 per 100 pt-years in the RIB and PBO arms, respectively. The most common all-causality Grade 3/4 AEs (≥10% in any arm; RIB vs PBO) were neutropenia (59% vs 2%), leukopenia (18% vs 1%), and hypertension (13% vs 13%). A new Fridericia's corrected QT interval (QTcF) >480 ms occurred in (n/N) 52/1054 (5%) vs 11/814 (1%) pts in the RIB vs PBO arms; a new QTcF >500 ms occurred in 14/1054 (1%) vs 1/814 (<1%) pts. Median time to first event for Grade ≥2 neutropenia, elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and QTc prolongation in the RIB arm was 2, 12, and 2 weeks, respectively; median duration of first Grade ≥2 event was 4, 4, and 2 weeks. In the RIB arm vs PBO arms, 7% vs 3% of pts discontinued study treatment due to AEs; common all-grade AEs leading to RIB/PBO discontinuation (≥2% in any arm) were elevated ALT (4% vs <1%) and elevated AST (2% vs 1%). Discontinuation due to QT prolongation occurred in 4 pts in the RIB arm and 2 in the PBO arm (both <1%). All-grade serious AEs occurred in 25% of pts in the RIB arm vs 15% of pts in the PBO arm.
Conclusions: RIB in combination with various ET partners continues to demonstrate a predictable and manageable tolerability profile across a broad population of pts with HR+, HER2– ABC.
Citation Format: Burris HA, Chan A, Im S-A, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-15.
Collapse
Affiliation(s)
- HA Burris
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Chan
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S-A Im
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S Chia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - D Tripathy
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - FJ Esteva
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - M Campone
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Bardia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - O Kong
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - W Bao
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - I Diaz-Padilla
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - K Rodriguez Lorenc
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - DA Yardley
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| |
Collapse
|
22
|
Wachter R, Michele S, Witte K, Straburzynska-Migaj E, Belohlavek J, Fonseca C, Mueller C, Lonn E, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D. In-Hospital Initiation of Sacubitril/Valsartan in Stabilised Patients with Heart Failure and Reduced Ejection Fraction Naïve to Renin-Angiotensin System Blocker: An Analysis of the Transition Study. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Wachter R, Michele S, Witte K, Straburzynska-Migaj E, Belohlavek J, Fonseca C, Mueller C, Lonn E, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D. Initiation of Sacubitril/Valsartan in Patients with De Novo Heart Failure with Reduced Ejection Fraction: An Analysis of the Transition Study. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 2018; 179:1205-1207. [PMID: 29927479 DOI: 10.1111/bjd.16901] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- R B Warren
- The Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Biomedical Research Centre, The University of Manchester, Manchester, U.K
| | - K Reich
- Dermatologikum Berlin and SCIDerm Research Institute, Hamburg, Germany
| | - R G Langley
- Dalhousie University, Halifax, NS, B3H, Canada
| | - B Strober
- University of Connecticut Health Center, Farmington, CT, U.S.A.,Probity Medical Research, Waterloo, ON, Canada
| | - D Gladman
- Toronto Western Hospital, Toronto, ON, Canada
| | - A Deodhar
- Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, U.S.A
| | | | - W Bao
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A
| | | | - S Hussain
- Novartis Healthcare Pvt Ltd, Hyderabad, India
| | - J Safi
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A
| |
Collapse
|
25
|
Zhang B, Li C, Bao W, Li Y, Tian S, Qiu X, Bai Y. Exercise brings balance of glucose metabolism to bilateral motor pathways in cerebral ischemic rat: A preliminary study using micropet. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Yeomans ND, Graham DY, Husni ME, Solomon DH, Stevens T, Vargo J, Wang Q, Wisniewski LM, Wolski KE, Borer JS, Libby P, Lincoff AM, Lüscher TF, Bao W, Walker C, Nissen SE. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther 2018; 47:1453-1463. [PMID: 29667211 DOI: 10.1111/apt.14610] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 12/09/2017] [Accepted: 02/21/2018] [Indexed: 12/18/2022]
Abstract
AIM To evaluate GI safety of celecoxib compared with 2 nonselective (ns) NSAIDs, as a secondary objective of a large trial examining multiorgan safety. METHODS This randomised, double-blind controlled trial analysed 24 081 patients. Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b.d., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already prescribed. Clinically significant GI events (CSGIE-bleeding, obstruction, perforation events from stomach downwards or symptomatic ulcers) and iron deficiency anaemia (IDA) were adjudicated blindly. RESULTS Mean treatment and follow-up durations were 20.3 and 34.1 months. While on treatment or 30 days after, CSGIE occurred in 0.34%, 0.74% and 0.66% taking celecoxib, ibuprofen and naproxen. Hazard ratios (HR) were 0.43 (95% CI 0.27-0.68, P = 0.0003) celecoxib vs ibuprofen and 0.51 (0.32-0.81, P = 0.004) vs naproxen. There was also less IDA on celecoxib: HR 0.43 (0.27-0.68, P = 0.0003) vs ibuprofen; 0.40 (0.25-0.62, P < 0.0001) vs naproxen. Even taken with low-dose aspirin, fewer CSGIE occurred on celecoxib than ibuprofen (HR 0.52 [0.29-0.94], P = 0.03), and less IDA vs naproxen (0.42 [0.23-0.77, P = 0.005]). Corticosteroid use increased total GI events and CSGIE. H. pylori serological status had no influence. CONCLUSIONS Arthritis patients taking NSAIDs plus esomeprazole have infrequent clinically significant gastrointestinal events. Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite treatment with low-dose aspirin or corticosteroids.
Collapse
Affiliation(s)
- N D Yeomans
- Department of Medicine, Austin Hospital, University of Melbourne, Melbourne, Victoria, Australia
- Western Sydney University, Campbelltown, NSW, Australia
| | - D Y Graham
- Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, USA
| | - M E Husni
- Cleveland Clinic, Cleveland, OH, USA
| | - D H Solomon
- Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA
| | - T Stevens
- Cleveland Clinic, Cleveland, OH, USA
| | - J Vargo
- Cleveland Clinic, Cleveland, OH, USA
| | - Q Wang
- Cleveland Clinic, Cleveland, OH, USA
| | | | | | - J S Borer
- Downstate College of Medicine, State University of New York, New York, NY, USA
| | - P Libby
- Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA
| | | | - T F Lüscher
- Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
| | - W Bao
- Pfizer, New York, NY, USA
| | | | | | | |
Collapse
|
27
|
Zhan P, Dukik K, Li D, Sun J, Stielow JB, Gerrits van den Ende B, Brankovics B, Menken SBJ, Mei H, Bao W, Lv G, Liu W, de Hoog GS. Phylogeny of dermatophytes with genomic character evaluation of clinically distinct Trichophyton rubrum and T. violaceum. Stud Mycol 2018; 89:153-175. [PMID: 29910521 PMCID: PMC6002342 DOI: 10.1016/j.simyco.2018.02.004] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Trichophyton rubrum and T. violaceum are prevalent agents of human dermatophyte infections, the former being found on glabrous skin and nail, while the latter is confined to the scalp. The two species are phenotypically different but are highly similar phylogenetically. The taxonomy of dermatophytes is currently being reconsidered on the basis of molecular phylogeny. Molecular species definitions do not always coincide with existing concepts which are guided by ecological and clinical principles. In this article, we aim to bring phylogenetic and ecological data together in an attempt to develop new species concepts for anthropophilic dermatophytes. Focus is on the T. rubrum complex with analysis of rDNA ITS supplemented with LSU, TUB2, TEF3 and ribosomal protein L10 gene sequences. In order to explore genomic differences between T. rubrum and T. violaceum, one representative for both species was whole genome sequenced. Draft sequences were compared with currently available dermatophyte genomes. Potential virulence factors of adhesins and secreted proteases were predicted and compared phylogenetically. General phylogeny showed clear gaps between geophilic species of Arthroderma, but multilocus distances between species were often very small in the derived anthropophilic and zoophilic genus Trichophyton. Significant genome conservation between T. rubrum and T. violaceum was observed, with a high similarity at the nucleic acid level of 99.38 % identity. Trichophyton violaceum contains more paralogs than T. rubrum. About 30 adhesion genes were predicted among dermatophytes. Seventeen adhesins were common between T. rubrum and T. violaceum, while four were specific for the former and eight for the latter. Phylogenetic analysis of secreted proteases reveals considerable expansion and conservation among the analyzed species. Multilocus phylogeny and genome comparison of T. rubrum and T. violaceum underlined their close affinity. The possibility that they represent a single species exhibiting different phenotypes due to different localizations on the human body is discussed.
Collapse
Affiliation(s)
- P Zhan
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.,Dermatology Hospital of Jiangxi Provinces, Jiangxi Dermatology Institute, Nanchang, China.,Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - K Dukik
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - D Li
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.,Georgetown University Medical Center, Department of Microbiology and Immunology, Washington, DC, USA
| | - J Sun
- Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China
| | - J B Stielow
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Thermo Fisher Scientific, Landsmeer, The Netherlands.,Center of Expertise in Mycology of Radboudumc/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | | | - B Brankovics
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - S B J Menken
- Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - H Mei
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China
| | - W Bao
- Nanjing General Hospital of Nanjing Command, Nanjing, China
| | - G Lv
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China
| | - W Liu
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China
| | - G S de Hoog
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands.,Thermo Fisher Scientific, Landsmeer, The Netherlands.,Center of Expertise in Mycology of Radboudumc/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| |
Collapse
|
28
|
Liu Y, Bao W. AWARENESS OF ALZHEIMER’S DISEASE AMONG NURSES WORKING IN GENERAL HOSPITAL IN BEIJING, CHINA. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.3315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y. Liu
- School of Nursing,Peking University, Beijing, China,
| | - W. Bao
- Beijing Hospital, Beijing, China
| |
Collapse
|
29
|
Shi QY, Feng X, Wang JJ, Wang X, Bao W, Ma J, Shi QL. [MGMT expression in primary central nervous system diffuse large B cell lymphoma and its relationship with prognosis]. Zhonghua Bing Li Xue Za Zhi 2016; 45:850-853. [PMID: 28056300 DOI: 10.3760/cma.j.issn.0529-5807.2016.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To study the correlation between MGMT expression, clinicopathologic features and post-chemotherapy prognosis in patients with primary central nervous system lymphoma diffuse large B-cell lymphoma (PCNS-DLBCL). Methods: MGMT expression was detected in 76 cases of PCNS-DLBCL by EnVision method with immunohistochemical staining.Follow-up data including treatment response and overall survival time, were analyzed. Results: The rate of MGMT expression in PCNS-DLBCL was 67.1%(51/76). The MGMT expression rate in male patients was higher than that in female(P<0.05). Univariate analysis showed that these clinical pathological characteristics affected the overall survival of PCNS-DLBCL patients, including age and Hans algorithm, although no statistical significance was detected(P value was 0.065 and 0.069 respectively). The overall survival of the patients with positive MGMT and aged over 60 years was shorter after chemotherapy than those without chemotherapy (P=0.022). In the patients aged over 60 years, the prognosis of MGMT-positive patients was significantly better than MGMT-negative patients (P=0.044). Conclusions: The expression of MGMT is more commonly found in male patients. In the patients aged over 60 years with the same therapy, the prognosis is better in the MGMT-negative ones. Detection of MGMT protein expression can provide some guidance in choice of treatment modalities in PCNS-DLBCL patients.
Collapse
Affiliation(s)
- Q Y Shi
- Department of Pathology, Nanjing General Hospital of Nanjing Military Region, Nanjing Medical University, Nanjing 210002, China
| | | | | | | | | | | | | |
Collapse
|
30
|
Tobias DK, Zhang C, Chavarro J, Olsen S, Bao W, Bjerregaard AA, Fung TT, Manson JE, Hu FB. Healthful dietary patterns and long-term weight change among women with a history of gestational diabetes mellitus. Int J Obes (Lond) 2016; 40:1748-1753. [PMID: 27569683 PMCID: PMC5101125 DOI: 10.1038/ijo.2016.156] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Revised: 07/21/2016] [Accepted: 07/29/2016] [Indexed: 12/30/2022]
Abstract
BACKGROUND/OBJECTIVE Diet represents a key strategy for the prevention of obesity and type 2 diabetes among women with a history of gestational diabetes mellitus (GDM), although effective dietary patterns to prevent weight gain in the long term are largely unknown. We sought to evaluate whether improvement in overall diet quality is associated with less long-term weight gain among high-risk women with prior GDM. SUBJECTS/METHODS Women with a history of GDM (N=3397) were followed from 1991 to 2011, or until diagnosis of type 2 diabetes or other chronic disease. Usual diet was assessed via food frequency questionnaire every 4 years from which we calculated the Alternative Healthy Eating Index (aHEI-2010), Alternate Mediterranean Diet (AMED) and Dietary Approaches to Stop Hypertension (DASH) dietary pattern scores. Weight, lifestyle and health-related outcomes were self-reported every 2 years. We estimated the change in dietary score with change in body weight using linear regression models adjusting for age, baseline body mass index (BMI), baseline and simultaneous change in physical activity and smoking status and other risk factors. RESULTS Women were followed up to 20 years, gaining an average 1.9 kg (s.d.=7.0) per 4-year period. Women in the highest quintile (Q5) of diet change (most improvement in quality) gained significantly less weight per 4-year period than the lowest quintile (Q1; decrease in quality), independent of other risk factors (4-year weight change, aHEI-2010: Q5=1.30 kg vs Q1=3.27 kg; AMED: Q5=0.94 kg vs Q1=2.56 kg, DASH: Q5=0.64 kg vs Q1=2.75 kg). Significant effect modification by BMI (p-interactions <0.001) indicated a greater magnitude of weight change among women with a higher baseline BMI for all three patterns. CONCLUSIONS Increased diet quality was associated with less weight gain, independent of other lifestyle factors. Post-partum recommendations on diet quality may provide one strategy to prevent long-term weight gain in this high-risk group.
Collapse
Affiliation(s)
- D K Tobias
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - C Zhang
- Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, USA
| | - J Chavarro
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - S Olsen
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Centre for Fetal Programming, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
| | - W Bao
- Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, USA
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA
| | - A A Bjerregaard
- Centre for Fetal Programming, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
| | - T T Fung
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Department of Nutrition, Simmons College, Boston, MA, USA
| | - J E Manson
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - F B Hu
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| |
Collapse
|
31
|
Abstract
Quercus fabri is a pioneer species of secondary succession in evergreen broadleaved forests in China. In this study, we isolated and developed 12 polymorphic and 2 monomorphic microsatellite loci for Q. fabri using the biotin-streptavidin capture method. We characterized 12 polymorphic loci in 52 individuals from two populations. The number of alleles per locus ranged from 3 to 23. The observed and expected heterozygosities per locus were 0.033-0.773 and 0.138-0.924, respectively. These microsatellite loci will facilitate the studies on genetic variation, mating system, and gene flow of Q. fabri.
Collapse
Affiliation(s)
- Z Z Xiao
- School of Ecological and Environmental Sciences, Tiantong National Station of Forest Ecosystem, Shanghai Key Laboratory for Urban Ecology and Restoration, East China Normal University, Shanghai, China
| | - W W Chen
- School of Ecological and Environmental Sciences, Tiantong National Station of Forest Ecosystem, Shanghai Key Laboratory for Urban Ecology and Restoration, East China Normal University, Shanghai, China
| | - W Bao
- School of Ecological and Environmental Sciences, Tiantong National Station of Forest Ecosystem, Shanghai Key Laboratory for Urban Ecology and Restoration, East China Normal University, Shanghai, China
| | - R Wang
- School of Ecological and Environmental Sciences, Tiantong National Station of Forest Ecosystem, Shanghai Key Laboratory for Urban Ecology and Restoration, East China Normal University, Shanghai, China
| | - Y Y Li
- School of Ecological and Environmental Sciences, Tiantong National Station of Forest Ecosystem, Shanghai Key Laboratory for Urban Ecology and Restoration, East China Normal University, Shanghai, China
| |
Collapse
|
32
|
Johnson TH, Yuan Y, Bao W, Clark SR, Foot C, Jaksch D. Hubbard Model for Atomic Impurities Bound by the Vortex Lattice of a Rotating Bose-Einstein Condensate. Phys Rev Lett 2016; 116:240402. [PMID: 27367366 DOI: 10.1103/physrevlett.116.240402] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/01/2016] [Indexed: 06/06/2023]
Abstract
We investigate cold bosonic impurity atoms trapped in a vortex lattice formed by condensed bosons of another species. We describe the dynamics of the impurities by a bosonic Hubbard model containing occupation-dependent parameters to capture the effects of strong impurity-impurity interactions. These include both a repulsive direct interaction and an attractive effective interaction mediated by the Bose-Einstein condensate. The occupation dependence of these two competing interactions drastically affects the Hubbard model phase diagram, including causing the disappearance of some Mott lobes.
Collapse
Affiliation(s)
- T H Johnson
- Centre for Quantum Technologies, National University of Singapore, 117543 Singapore
- Clarendon Laboratory, University of Oxford, Parks Road, Oxford OX1 3PU, United Kingdom
- Keble College, University of Oxford, Parks Road, Oxford OX1 3PG, United Kingdom
| | - Y Yuan
- Beijing Computational Science Research Center, Beijing 100094, China
- Department of Mathematics, National University of Singapore, 119076 Singapore
- College of Mathematics and Computer Science, Synthetic Innovation Center for Quantum Effects and Applications, Hunan Normal University, Changsha, Hunan Province 410081, China
| | - W Bao
- Department of Mathematics, National University of Singapore, 119076 Singapore
| | - S R Clark
- Keble College, University of Oxford, Parks Road, Oxford OX1 3PG, United Kingdom
- Department of Physics, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
| | - C Foot
- Clarendon Laboratory, University of Oxford, Parks Road, Oxford OX1 3PU, United Kingdom
| | - D Jaksch
- Centre for Quantum Technologies, National University of Singapore, 117543 Singapore
- Clarendon Laboratory, University of Oxford, Parks Road, Oxford OX1 3PU, United Kingdom
- Keble College, University of Oxford, Parks Road, Oxford OX1 3PG, United Kingdom
| |
Collapse
|
33
|
Dai Z, Bao W, Li S, Li H, Jiang J, Chen S. Enhancement of Polyethylene Terephthalate Artificial Ligament Graft Osseointegration using a Periosteum Patch in a Goat Model. Int J Sports Med 2016; 37:493-9. [PMID: 26990720 DOI: 10.1055/s-0042-102258] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Z. Dai
- Department of Sports Medicine, Huashan Hospital Fudan University, Shanghai, China
| | - W. Bao
- Department of PET Center, Huashan Hospital, Fudan University, Shanghai, China
| | - S. Li
- Department of Sports Medicine, Huashan Hospital Fudan University, Shanghai, China
| | - H. Li
- Department of Sports Medicine, Huashan Hospital Fudan University, Shanghai, China
| | - J. Jiang
- Department of Sports Medicine, Huashan Hospital Fudan University, Shanghai, China
| | - S. Chen
- Department of Sports Medicine, Huashan Hospital Fudan University, Shanghai, China
| |
Collapse
|
34
|
Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther 2015; 42:829-44. [PMID: 26238707 DOI: 10.1111/apt.13342] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Revised: 03/29/2015] [Accepted: 07/08/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. AIM To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naïve patients with chronic HCV genotype 1 infection. METHODS Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily [response-guided therapy (RGT) for 24 or 48 weeks or 48 weeks fixed duration] or ALV 400 mg twice daily RGT with PR, compared to PR alone. Following a Food and Drug Administration partial clinical hold, ALV/placebo was discontinued and patients completed treatment with PR only. At that time, 87% of patients had received ≥12 weeks and 20% had received ≥24 weeks of ALV/PR triple therapy. RESULTS A total of 1081 patients were randomised (12% cirrhosis, 55% CT/TT IL28B). Addition of ALV to PR improved virological response in a dose-dependent fashion. Overall, sustained virological response (SVR12; primary endpoint) was 69% in all ALV groups vs. 53% in PR control. Highest SVR12 (90%) was achieved in patients treated with ALV 400 mg twice daily and PR for >24 weeks. Seven cases of pancreatitis were reported, with similar frequency between ALV/PR and PR control groups (0.6% vs. 0.8% respectively). Adverse events seen more frequently with ALV/PR than with PR alone were anaemia, thrombocytopenia, hyperbilirubinaemia and hypertension. CONCLUSIONS Alisporivir, especially the 400 mg twice daily regimen, increased efficacy of PR therapy in treatment-naïve patients with HCV genotype 1 infection. The mechanism of action and pangenotypic activity suggest that alisporivir could be useful in interferon-free combination regimens.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - B Nault
- Novartis Pharma AG, Basel, Switzerland
| | - M Merz
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - W Bao
- Novartis Pharmaceuticals, East Hanover, NJ, USA
| | - L H Griffel
- Novartis Pharmaceuticals, East Hanover, NJ, USA
| | - C Brass
- Novartis Pharmaceuticals, East Hanover, NJ, USA
| | | | | |
Collapse
|
35
|
Fei Z, Iwinski EG, Ni GX, Zhang LM, Bao W, Rodin AS, Lee Y, Wagner M, Liu MK, Dai S, Goldflam MD, Thiemens M, Keilmann F, Lau CN, Castro-Neto AH, Fogler MM, Basov DN. Tunneling Plasmonics in Bilayer Graphene. Nano Lett 2015. [PMID: 26222509 DOI: 10.1021/acs.nanolett.5b00912] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
We report experimental signatures of plasmonic effects due to electron tunneling between adjacent graphene layers. At subnanometer separation, such layers can form either a strongly coupled bilayer graphene with a Bernal stacking or a weakly coupled double-layer graphene with a random stacking order. Effects due to interlayer tunneling dominate in the former case but are negligible in the latter. We found through infrared nanoimaging that bilayer graphene supports plasmons with a higher degree of confinement compared to single- and double-layer graphene, a direct consequence of interlayer tunneling. Moreover, we were able to shut off plasmons in bilayer graphene through gating within a wide voltage range. Theoretical modeling indicates that such a plasmon-off region is directly linked to a gapped insulating state of bilayer graphene, yet another implication of interlayer tunneling. Our work uncovers essential plasmonic properties in bilayer graphene and suggests a possibility to achieve novel plasmonic functionalities in graphene few-layers.
Collapse
Affiliation(s)
- Z Fei
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| | - E G Iwinski
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| | - G X Ni
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
- ‡Graphene Research Centre, National University of Singapore, 117542, Singapore
| | - L M Zhang
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
- §Department of Physics, Boston University, Boston, Massachusetts 02215, United States
| | - W Bao
- ∥Department of Physics and Astronomy, University of California, Riverside, California 92521, United States
| | - A S Rodin
- §Department of Physics, Boston University, Boston, Massachusetts 02215, United States
| | - Y Lee
- ∥Department of Physics and Astronomy, University of California, Riverside, California 92521, United States
| | - M Wagner
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| | - M K Liu
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
- ⊥Department of Physics, Stony Brook University, Stony Brook, New York 11794, United States
| | - S Dai
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| | - M D Goldflam
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| | - M Thiemens
- #Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States
| | - F Keilmann
- ∇Ludwig-Maximilians-Universität and Center for Nanoscience, 80539 München, Germany
| | - C N Lau
- ∥Department of Physics and Astronomy, University of California, Riverside, California 92521, United States
| | - A H Castro-Neto
- ‡Graphene Research Centre, National University of Singapore, 117542, Singapore
- §Department of Physics, Boston University, Boston, Massachusetts 02215, United States
| | - M M Fogler
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| | - D N Basov
- †Department of Physics, University of California, San Diego, La Jolla, California 92093, United States
| |
Collapse
|
36
|
Lu XF, Wang NZ, Wu H, Wu YP, Zhao D, Zeng XZ, Luo XG, Wu T, Bao W, Zhang GH, Huang FQ, Huang QZ, Chen XH. Coexistence of superconductivity and antiferromagnetism in (Li0.8Fe0.2)OHFeSe. Nat Mater 2015; 14:325-329. [PMID: 25502096 DOI: 10.1038/nmat4155] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Accepted: 10/30/2014] [Indexed: 06/04/2023]
Abstract
Iron selenide superconductors exhibit a number of unique characteristics that are helpful for understanding the mechanism of superconductivity in high-Tc iron-based superconductors more generally. However, in the case of AxFe2Se2 (A = K, Rb, Cs), the presence of an intergrown antiferromagnetic insulating phase makes the study of the underlying physics problematic. Moreover, FeSe-based systems intercalated with alkali metal ions, NH3 molecules or organic molecules are extremely sensitive to air, which prevents the further investigation of their physical properties. It is therefore desirable to find a stable and easily accessible FeSe-based superconductor to study its physical properties in detail. Here, we report the synthesis of an air-stable material, (Li0.8Fe0.2)OHFeSe, which remains superconducting at temperatures up to ~40 K, by means of a novel hydrothermal method. The crystal structure is unambiguously determined by a combination of X-ray and neutron powder diffraction and nuclear magnetic resonance. Moreover, antiferromagnetic order is shown to coexist with superconductivity. This synthetic route opens a path for exploring superconductivity in other related systems, and confirms the appeal of iron selenides as a platform for understanding superconductivity in iron pnictides more broadly.
Collapse
Affiliation(s)
- X F Lu
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China
| | - N Z Wang
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China
| | - H Wu
- 1] National Institute of Standards and Technology, Center for Neutron Research, 100 Bureau Dr., Gaithersburg Maryland 20878, USA [2] Department of Materials Science and Engineering, University of Maryland, College Park, Maryland 20742, USA
| | - Y P Wu
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China
| | - D Zhao
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China
| | - X Z Zeng
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China
| | - X G Luo
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China [3] Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing 210093, China
| | - T Wu
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China [3] Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing 210093, China
| | - W Bao
- Department of Physics, Renmin University of China, Beijing 100872, China
| | - G H Zhang
- 1] CAS Key Laboratory of Materials for Energy Conversion, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, China [2] Beijing National Laboratory for Molecular Sciences and State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | - F Q Huang
- 1] CAS Key Laboratory of Materials for Energy Conversion, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, China [2] Beijing National Laboratory for Molecular Sciences and State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | - Q Z Huang
- National Institute of Standards and Technology, Center for Neutron Research, 100 Bureau Dr., Gaithersburg Maryland 20878, USA
| | - X H Chen
- 1] Hefei National Laboratory for Physical Sciences at Microscale and Department of Physics, University of Science and Technology of China, Hefei, Anhui 230026, China [2] Key Laboratory of Strongly-coupled Quantum Matter Physics, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui 230026, China [3] Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing 210093, China
| |
Collapse
|
37
|
Kano H, Okada K, Morimoto K, Bao W, Fukase K, Ito A, Okita Y. Prediction of reversibility of intestinal mucosal damage after ischemia-reperfusion injury by plasma intestinal fatty acid-binding protein levels in pigs. Perfusion 2014; 30:617-25. [DOI: 10.1177/0267659114566063] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Objective: The aims of this study were to elucidate the association between plasma intestinal fatty acid-binding protein (I-FABP) level and actual pathological damage of intestinal mucosa and its reversibility. Methods: An intestinal ischemia-reperfusion model was created by temporary occlusion of the descending aorta in 9 pigs which were divided into 3 groups according to the duration of visceral ischemic insult: 15-minute ischemia (n=3), 30-minute ischemia (n=3) and 60-minute ischemia (n=3). Blood samples and short segments of the jejunum for pathological examinations, including immunohistochemical staining of I-FABP, Ki-67 and E-cadherin, were taken at the beginning of the operation (T1) and 15 minutes (T2), 30 minutes (T3), 45 minutes (T4) and 60 minutes (T5) after reperfusion. Results: Plasma I-FABP after 15 minutes of ischemia reached a peak of 1859±1089 pg/ml at T3, while the level after 30 minutes of ischemia achieved a peak level of 5053±1717 pg/ml at T5. The level after 60 minutes of ischemia demonstrated a rapid increment up to 10734±93 pg/ml at T3. There was a significant difference in the trend of plasma I-FABP levels between 30 minutes and 60 minutes of ischemia (p=0.01). The strongest immunohistochemical staining of the intestinal epithelium for I-FABP was observed at T4 after 30 minutes of ischemia, with the shedding of injured epithelium followed by re-epithelialisation, with sequential up-regulation of Ki67 and E-cadherin. However, the intestinal epithelium after 60 minutes of ischemia demonstrated the lack of I-FABP expression with irreversible damage. Conclusion: Plasma I-FABP levels may be a crucial marker to recognize the reversibility of damage of the intestinal epithelium after an ischemic insult and the level of 5000 pg/ml is considered to be the critical borderline for irreversibility, which might prevent diagnostic delay in the clinical setting.
Collapse
Affiliation(s)
- H Kano
- Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - K Okada
- Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - K Morimoto
- Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - W Bao
- Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - K Fukase
- Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - A Ito
- Department of Pathology, Kinki University Faculty of Medicine, Osaka, Japan
| | - Y Okita
- Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
38
|
Abstract
Abstract
In this paper, ultrasound was applied in extrusion reaction processing to graft an Elastomer (DE) with maleic anhydride (MAH), in order to improve the non-polarity of DE. Two types of DE-g-MAH were prepared by different methods and had similar grafting degree about 0.2 % and then they were added into the polyamide-6/elastomer (PA6/DE) blends, respectively. The effect of DE-g-MAH on the interfacial properties of PA6/DE blends was studied. The experimental results showed that, compared to the DE-g-MAH initiated by peroxide, DE-g-MAH initiated by ultrasound had better effect on refining the particle size of the dispersion phase and keeping the stability of the phase in the blends, which could be confirmed through SEM and Molau tests. When 5 % DE-g-MAH initiated by peroxide was added, the particle size of dispersion phase was 3.90 μm, however, when 5 % DE-g-MAH initiated by ultrasound was added, the particle size of dispersion phase was 2.82 μm. The results of TGA and mechanical tests showed the improved interfacial interaction and enhanced interfacial adhesion of the blend by adding DE-g-MAH, respectively.
Collapse
Affiliation(s)
- W. Bao
- The State Key Laboratory of Polymer Materials Engineering , Polymer Research Institute of Sichuan University, Chengdu , PRC
| | - H. Wu
- The State Key Laboratory of Polymer Materials Engineering , Polymer Research Institute of Sichuan University, Chengdu , PRC
| | - T. Xie
- The State Key Laboratory of Polymer Materials Engineering , Polymer Research Institute of Sichuan University, Chengdu , PRC
| | - S. Guo
- The State Key Laboratory of Polymer Materials Engineering , Polymer Research Institute of Sichuan University, Chengdu , PRC
| |
Collapse
|
39
|
|
40
|
Arsenault B, Boekholdt SM, Mora S, Demicco DA, Bao W, Tardif JC, Amarenco P, Pedersen TR, Barter P, Waters D. Clinical determinants of incident aortic valve stenosis in patients treated with atorvastatin: results from three large randomized clinical trials. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p4716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
41
|
Melli M, Polyakov A, Gargas D, Huynh C, Scipioni L, Bao W, Ogletree DF, Schuck PJ, Cabrini S, Weber-Bargioni A. Reaching the theoretical resonance quality factor limit in coaxial plasmonic nanoresonators fabricated by helium ion lithography. Nano Lett 2013; 13:2687-2691. [PMID: 23617768 DOI: 10.1021/nl400844a] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Optical antenna structures have revolutionized the field of nano-optics by confining light to deep subwavelength dimensions for spectroscopy and sensing. In this work, we fabricated coaxial optical antennae with sub-10-nanometer critical dimensions using helium ion lithography (HIL). Wavelength dependent transmission measurements were used to determine the wavelength-dependent optical response. The quality factor of 11 achieved with our HIL fabricated structures matched the theoretically predicted quality factor for the idealized flawless gold resonators calculated by finite-difference time-domain (FDTD). For comparison, coaxial antennae with 30 nm critical dimensions were fabricated using both HIL and the more common Ga focus ion beam lithography (Ga-FIB). The quality factor of the Ga-FIB resonators was 60% of the ideal HIL results for the same design geometry due to limitations in the Ga-FIB fabrication process.
Collapse
Affiliation(s)
- M Melli
- Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Lee Y, Velasco J, Tran D, Zhang F, Bao W, Jing L, Myhro K, Smirnov D, Lau CN. Broken symmetry quantum Hall states in dual-gated ABA trilayer graphene. Nano Lett 2013; 13:1627-1631. [PMID: 23527578 DOI: 10.1021/nl4000757] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
ABA-stacked trilayer graphene is a unique 2D electron system with mirror reflection symmetry and unconventional quantum Hall effect. We present low-temperature transport measurements on dual-gated suspended trilayer graphene in the quantum Hall (QH) regime. We observe QH plateaus at filling factors ν = -8, -2, 2, 6, and 10, which is in agreement with the full-parameter tight binding calculations. In high magnetic fields, odd-integer plateaus are also resolved, indicating almost complete lifting of the 12-fold degeneracy of the lowest Landau level (LL). Under an out-of-plane electric field E(perpendicular), we observe degeneracy breaking and transitions between QH plateaus. Interestingly, depending on its direction, E(perpendicular) selectively breaks the LL degeneracies in the electron-doped or hole-doped regimes. Our results underscore the rich interaction-induced phenomena in trilayer graphene.
Collapse
Affiliation(s)
- Yongjin Lee
- Department of Physics and Astronomy, University of California, Riverside, Riverside, California 92521, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HLY, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013; 20:e37-46. [PMID: 23490388 PMCID: PMC3618368 DOI: 10.1111/jvh.12025] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 10/01/2012] [Indexed: 12/16/2022]
Abstract
In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%) of telbivudine-treated patients, who were serum HBV DNA positive or negative and without genotypic resistance to telbivudine at the end of the GLOBE/015 trials, were enrolled into a further 2-year extension study. A group of 502 patients completed 4 years of continuous telbivudine treatment and were included in the telbivudine per-protocol population. Amongst 293 HBeAg-positive patients, 76.2% had undetectable serum HBV DNA and 86.0% had normal serum ALT at the end of 4 years. Notably, the cumulative rate of HBeAg seroconversion was 53.2%. Amongst 209 HBeAg-negative patients, 86.4% had undetectable HBV DNA and 89.6% had normal serum ALT. In patients who had discontinued telbivudine treatment due to HBeAg seroconversion, the HBeAg response was durable in 82% of patients (median 111 weeks of off-treatment follow-up). The cumulative 4-year resistance rate was 10.6% for HBeAg-positive and 10.0% for HBeAg-negative patients. Most adverse events were mild or moderate in severity and transient. Renal function measured by estimated glomerular filtration rate (eGFR) increased by 14.9 mL/min/1.73 m(2) (16.6%) from baseline to 4 years (P < 0.0001). In conclusion, in HBeAg-positive and HBeAg-negative CHB patients without resistance after 2 years, two additional years of telbivudine treatment continued to provide effective viral suppression with a favourable safety profile. Moreover, telbivudine achieved 53% of HBeAg seroconversion in HBeAg-positive patients.
Collapse
Affiliation(s)
- Y Wang
- Institute of Infectious Diseases, Southwest Hospital, Third Military Medical UniversityChongqing, China
| | - S Thongsawat
- Department of Internal Medicine, Faculty of Medicine, Chiang Mai UniversityChiang Mai, Thailand
| | - E J Gane
- New Zealand Liver Unit, Auckland City HospitalAuckland, New Zealand
| | - Y-F Liaw
- Liver Research Unit, Chang Gung Memorial Hospital & UniversityTaipei, Taiwan
| | - J Jia
- Liver Research Center, Beijing Friendship Hospital, Capital Medical UniversityBeijing, China
| | - J Hou
- Hepatology Unit and Department of Infectious Diseases, Nanfang HospitalGuangzhou, China
| | - H L Y Chan
- Medicine and Therapeutics, Chinese University of Hong KongHong Kong, China
| | - G Papatheodoridis
- Academic Department of Medicine, Hippokration General HospitalAthens, Greece
| | - M Wan
- Department of Infectious Diseases, ChangHai Hospital of the Second Military Medical UniversityShanghai, China
| | - J Niu
- Department of Hepatology, First hospital of Jilin UniversityJilin, China
| | - W Bao
- Novartis Pharma CorporationEast Hanover, NJ, USA
| | | | | |
Collapse
|
44
|
Schuster B, Roszell L, Murr L, Ramirez D, Demaree J, Klotz B, Rosencrance A, Dennis W, Bao W, Perkins E, Dillman J, Bannon D. In vivo corrosion, tumor outcome, and microarray gene expression for two types of muscle-implanted tungsten alloys. Toxicol Appl Pharmacol 2012; 265:128-38. [DOI: 10.1016/j.taap.2012.08.025] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Revised: 08/17/2012] [Accepted: 08/27/2012] [Indexed: 11/25/2022]
|
45
|
Chan HLY, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19:732-43. [PMID: 22967105 DOI: 10.1111/j.1365-2893.2012.01600.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Patients with decompensated cirrhosis owing to chronic hepatitis B viral (HBV) infection have a high morbidity/mortality rate, and the treatment remains a challenge. We studied the safety and efficacy of telbivudine and lamivudine in such patients. This noninferiority, double-blind trial randomized 232 treatment-naive patients with decompensated HBV (1:1) in 80 academic hospitals to receive once-daily telbivudine 600 mg or lamivudine 100 mg for 104 weeks. Primary composite endpoint was proportion of patients with HBV DNA <10 000 copies/mL, normal alanine aminotransferase (ALT) and Child-Turcotte-Pugh score improvement/stabilization at week 52. Response rates using a post hoc modified endpoint (HBV DNA <300 copies/mL [57 IU/mL] and ALT normalization) in intent-to-treat analysis (missing = failure) were 56.3%vs 38.0% after 76 weeks (P = 0.018) and 45.6%vs 32.9% after 104 weeks (P = 0.093) for telbivudine vs lamivudine. Telbivudine treatment was an independent predictive factor for HBV DNA <300 copies/mL and ALT normalization (P = 0.037). Response rates with protocol-defined composite endpoint in intent-to-treat analysis (M = F) were 56.2 vs 54.0% (noninferiority not achieved) and 39.1%vs 36.4% (noninferiority achieved) in telbivudine and lamivudine groups at 52 and 104 weeks. Telbivudine treatment was associated with a significant improvement in glomerular filtration rate compared to lamivudine treatment and was also associated with a trend for improvement in survival (87%vs 79%). No cases of lactic acidosis were reported. Telbivudine compared to lamivudine was associated with a higher rate of patients with both viral suppression and ALT normalization, a trend towards a higher rate of survival and significant improvement in glomerular filtration.
Collapse
Affiliation(s)
- H L Y Chan
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Cheng RJ, DuPont C, Archer DF, Bao W, Racketa J, Constantine G, Pickar JH. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric 2012; 16:17-27. [DOI: 10.3109/13697137.2012.672495] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- R. J. Cheng
- Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, USA
| | - C. DuPont
- *DuPont Associates, Rockville, MD, USA
| | - D. F. Archer
- Eastern Virginia Medical School, Clinical Research Center, Norfolk, Virginia, USA
| | - W. Bao
- Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, USA
| | - J. Racketa
- Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, USA
| | | | - J. H. Pickar
- Columbia University Medical Center, New York, NY, USA
| |
Collapse
|
47
|
Xie K, Jia L, Xu D, Guo H, Xie X, Huang Y, Chen X, Bao W, Dai G, Wang J. Simultaneous Determination of Amoxicillin and Ampicillin in Eggs by Reversed-Phase High-Performance Liquid Chromatography with Fluorescence Detection using Pre-Column Derivatization. J Chromatogr Sci 2012; 50:620-4. [DOI: 10.1093/chromsci/bms052] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
48
|
Li H, Kilpeläinen TO, Liu C, Zhu J, Liu Y, Hu C, Yang Z, Zhang W, Bao W, Cha S, Wu Y, Yang T, Sekine A, Choi BY, Yajnik CS, Zhou D, Takeuchi F, Yamamoto K, Chan JC, Mani KR, Been LF, Imamura M, Nakashima E, Lee N, Fujisawa T, Karasawa S, Wen W, Joglekar CV, Lu W, Chang Y, Xiang Y, Gao Y, Liu S, Song Y, Kwak SH, Shin HD, Park KS, Fall CHD, Kim JY, Sham PC, Lam KSL, Zheng W, Shu X, Deng H, Ikegami H, Krishnaveni GV, Sanghera DK, Chuang L, Liu L, Hu R, Kim Y, Daimon M, Hotta K, Jia W, Kooner JS, Chambers JC, Chandak GR, Ma RC, Maeda S, Dorajoo R, Yokota M, Takayanagi R, Kato N, Lin X, Loos RJF. Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia 2012; 55:981-95. [PMID: 22109280 PMCID: PMC3296006 DOI: 10.1007/s00125-011-2370-7] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Accepted: 10/10/2011] [Indexed: 12/18/2022]
Abstract
AIMS/HYPOTHESIS FTO harbours the strongest known obesity-susceptibility locus in Europeans. While there is growing evidence for a role for FTO in obesity risk in Asians, its association with type 2 diabetes, independently of BMI, remains inconsistent. To test whether there is an association of the FTO locus with obesity and type 2 diabetes, we conducted a meta-analysis of 32 populations including 96,551 East and South Asians. METHODS All studies published on the association between FTO-rs9939609 (or proxy [r (2) > 0.98]) and BMI, obesity or type 2 diabetes in East or South Asians were invited. Each study group analysed their data according to a standardised analysis plan. Association with type 2 diabetes was also adjusted for BMI. Random-effects meta-analyses were performed to pool all effect sizes. RESULTS The FTO-rs9939609 minor allele increased risk of obesity by 1.25-fold/allele (p = 9.0 × 10(-19)), overweight by 1.13-fold/allele (p = 1.0 × 10(-11)) and type 2 diabetes by 1.15-fold/allele (p = 5.5 × 10(-8)). The association with type 2 diabetes was attenuated after adjustment for BMI (OR 1.10-fold/allele, p = 6.6 × 10(-5)). The FTO-rs9939609 minor allele increased BMI by 0.26 kg/m(2) per allele (p = 2.8 × 10(-17)), WHR by 0.003/allele (p = 1.2 × 10(-6)), and body fat percentage by 0.31%/allele (p = 0.0005). Associations were similar using dominant models. While the minor allele is less common in East Asians (12-20%) than South Asians (30-33%), the effect of FTO variation on obesity-related traits and type 2 diabetes was similar in the two populations. CONCLUSIONS/INTERPRETATION FTO is associated with increased risk of obesity and type 2 diabetes, with effect sizes similar in East and South Asians and similar to those observed in Europeans. Furthermore, FTO is also associated with type 2 diabetes independently of BMI.
Collapse
Affiliation(s)
- H. Li
- Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai-Yuan Road, Shanghai, 200031 People’s Republic of China
| | - T. O. Kilpeläinen
- MRC Epidemiology Unit, Institute of Metabolic Science Box 285, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ UK
| | - C. Liu
- Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai-Yuan Road, Shanghai, 200031 People’s Republic of China
| | - J. Zhu
- Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai-Yuan Road, Shanghai, 200031 People’s Republic of China
| | - Y. Liu
- Institutes of Biomedical Sciences, Fudan University, Shanghai, People’s Republic of China
| | - C. Hu
- Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
| | - Z. Yang
- Department of Endocrinology and Metabolism, Huashan Hospital, Institute of Endocrinology and Diabetology at Fudan University, Shanghai Medical School, Fudan University, Shanghai, People’s Republic of China
| | - W. Zhang
- Department Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - W. Bao
- Department of Nutrition and Food Hygiene and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
| | - S. Cha
- Division of Constitutional Medicine Research, Korea Institute of Oriental Medicine, Daejeon, South Korea
| | - Y. Wu
- Department of Genetics, University of North Carolina, Chapel Hill, NC USA
| | - T. Yang
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, and Institute of Molecular Genetics, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, People’s Republic of China
| | - A. Sekine
- EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - B. Y. Choi
- Department of Preventive Medicine, HanYang University College of Medicine, Seoul, South Korea
| | - C. S. Yajnik
- Diabetology Research Centre, KEM Hospital and Research Centre, Pune, India
| | - D. Zhou
- Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai-Yuan Road, Shanghai, 200031 People’s Republic of China
| | - F. Takeuchi
- National Center for Global Health and Medicine, Tokyo, Japan
| | - K. Yamamoto
- Division of Genome Analysis, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
| | - J. C. Chan
- Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region People’s Republic of China
| | - K. R. Mani
- Centre for Cellular and Molecular Biology (CCMB-CSIR), Hyderabad, India
| | - L. F. Been
- University of Oklahoma Health Sciences Center, Oklahoma City, OK USA
| | - M. Imamura
- Laboratory for Endocrinology and Metabolism, RIKEN Center for Genomic Medicine, Yokohama, Japan
| | - E. Nakashima
- Department of Diabetes and Endocrinology, Chubu Rosai Hospital, Nagoya, Japan
| | - N. Lee
- USC Office of Population Studies Foundation, University of San Carlos, Cebu, Philippines
| | - T. Fujisawa
- Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Japan
| | - S. Karasawa
- Third Department of Internal Medicine, and Global Center of Excellence Program Study Group, Yamagata University School of Medicine, Yamagata, Japan
| | - W. Wen
- Division of Epidemiology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN USA
| | - C. V. Joglekar
- Diabetology Research Centre, KEM Hospital and Research Centre, Pune, India
| | - W. Lu
- Shanghai Institute of Preventive Medicine, Shanghai, People’s Republic of China
| | - Y. Chang
- National Taiwan University Hospital Bei-Hu branch, Taipei, Taiwan
| | - Y. Xiang
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, People’s Republic of China
| | - Y. Gao
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, People’s Republic of China
| | - S. Liu
- Center for Metabolic Disease Prevention, School of Public Health and David Geffen School of Medicine, UCLA, Los Angeles, CA USA
| | - Y. Song
- Division of Preventive Medicine, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - S. H. Kwak
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
| | - H. D. Shin
- Department of Life Science, Sogang University, Seoul, South Korea
| | - K. S. Park
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
| | - C. H. D. Fall
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, Hampshire UK
| | - J. Y. Kim
- Division of Constitutional Medicine Research, Korea Institute of Oriental Medicine, Daejeon, South Korea
| | - P. C. Sham
- Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region People’s Republic of China
| | - K. S. L. Lam
- Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region People’s Republic of China
| | - W. Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN USA
| | - X. Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN USA
| | - H. Deng
- School of Medicine, University of Missouri, Kansas City, MO USA
- Center of Systematic Biomedical Research, University of Shanghai for Science and Technology, Shanghai, People’s Republic of China
- Institute of Bioscience and Biotechnology, School of Science, Beijing Jiaotong University, Beijing, People’s Republic of China
| | - H. Ikegami
- Department of Endocrinology, Metabolism and Diabetes, Kinki University School of Medicine, Osaka, Japan
| | - G. V. Krishnaveni
- Epidemiology Research Unit, Holdsworth Memorial Hospital, Mysore, India
| | - D. K. Sanghera
- University of Oklahoma Health Sciences Center, Oklahoma City, OK USA
| | - L. Chuang
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - L. Liu
- Department of Nutrition and Food Hygiene and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
| | - R. Hu
- Department of Endocrinology and Metabolism, Huashan Hospital, Institute of Endocrinology and Diabetology at Fudan University, Shanghai Medical School, Fudan University, Shanghai, People’s Republic of China
| | - Y. Kim
- Department of Preventive Medicine, Dong-A University College of Medicine, Busan, South Korea
| | - M. Daimon
- Third Department of Internal Medicine, and Global Center of Excellence Program Study Group, Yamagata University School of Medicine, Yamagata, Japan
| | - K. Hotta
- EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - W. Jia
- Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Clinical Center of Diabetes, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
| | - J. S. Kooner
- National Heart & Lung Institute, Hammersmith Hospital, Hammersmith Campus, Faculty of Medicine, Imperial College London, London, UK
| | - J. C. Chambers
- Department Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - G. R. Chandak
- Centre for Cellular and Molecular Biology (CCMB-CSIR), Hyderabad, India
| | - R. C. Ma
- Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region People’s Republic of China
| | - S. Maeda
- Laboratory for Endocrinology and Metabolism, RIKEN Center for Genomic Medicine, Yokohama, Japan
| | - R. Dorajoo
- Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Republic of Singapore
- Department of Genomics of Common Disease, School of Public Health, Hammersmith Hospital, Imperial College London, London, UK
| | - M. Yokota
- Department of Genome Science, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan
| | - R. Takayanagi
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - N. Kato
- National Center for Global Health and Medicine, Tokyo, Japan
| | - X. Lin
- Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai-Yuan Road, Shanghai, 200031 People’s Republic of China
| | - R. J. F. Loos
- MRC Epidemiology Unit, Institute of Metabolic Science Box 285, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ UK
| |
Collapse
|
49
|
Thampy V, Kang J, Rodriguez-Rivera JA, Bao W, Savici AT, Hu J, Liu TJ, Qian B, Fobes D, Mao ZQ, Fu CB, Chen WC, Ye Q, Erwin RW, Gentile TR, Tesanovic Z, Broholm C. Friedel-like oscillations from interstitial iron in superconducting Fe(1+y)Te0.62Se0.38. Phys Rev Lett 2012; 108:107002. [PMID: 22463442 DOI: 10.1103/physrevlett.108.107002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Indexed: 05/31/2023]
Abstract
Using polarized and unpolarized neutron scattering, we show that interstitial Fe in superconducting Fe(1+y)Te(1-x)Se(x) induces a magnetic Friedel-like oscillation that diffracts at Q⊥=(1/2 0) and involves >50 neighboring Fe sites. The interstitial >2μ(B) moment is surrounded by compensating ferromagnetic four-spin clusters that may seed double stripe ordering in Fe(1+y)Te. A semimetallic five-band model with (1/2 1/2) Fermi surface nesting and fourfold symmetric superexchange between interstitial Fe and two in-plane nearest neighbors largely accounts for the observed diffraction.
Collapse
Affiliation(s)
- V Thampy
- Institute for Quantum Matter and Department of Physics and Astronomy, Johns Hopkins University, Baltimore, Maryland 21218, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Rashid H, Abdel-Moniem A, Email S, El-Batran M, Rashid H, Mansour H, Mahmoud S, Ashour Z, Mustafa S, Khodeer SA, Abdu-Allah AM, Al-Assal M, Rashid HK, Ghosh Dastidar A, Garg P, West J, Muthusamy R, Gunn J, Zhu F, Lee A, Chee YE, Li ZJ, Kang CS, Chen ZY, Zhang YX, Zhao ZX, Song Q, Rong Y, Bao W, Shan ZL, Rong S, Wang D, Yao P, Liu LG, Zhu LX, Ho SC, Ruan GQ, Xie Q, Sit JWH, Yang YL, Chan MCH, Hu M, Chan TYK, Tomlinson B, Wu HS, Wang LS, Qin J, Wong TT, Heng PA, Yu CM, Luis SA, Luis CR, Habibian M, Courtney A, Hamilton-Craig C, Strugnell W, Poon K, Slaughter R, Raffel OC, Raffel OC, Luis SA, Hansen M, Slaughter R, Hamilton-Craig C, Liang Y, Bai Y, Chen T, Feng GX, Yang YM, Wang XY, Yang YJ, Zhu J, Al-Mohammadi M, Hersi A, Alhabib KF, Alsheikh-Ali AA, Sulaiman K, Alfaleh H, Alsaif S, Almahmeed W, Asaad N, Amin H, Al-Motarreb A, Al-Suwaid J, Blanco JRF, Velasco AB, Mancera J, Francisco A, CA, Zhuravlyova L, Lopina N, Song HH, Xu SH, Huang MZ, Xu CS, Xie LD, Ko B, Cameron J, Seneviratne S, Leung M, Antonis P, Koutsoubos J, Malaiapan Y, Meredith I, Capros N, Istrati V, Matcovschi S, Dumitras T, Istrati S, Nicolenco I, Hotineanu R, Manea D, Gherman O, Hsiung MC, Ko CH, Wei J, Tung TH, Graham CA, Chan JWM, Rotherary KR, Rainer TH, Yan B, Liu M, Huang XR, Li RJ, Lam YY, Yu CM. P033 * Evaluation of myocardial function in patients with chronic stable angina and apparent normal ventricular function (tissue doppler study before and after PCI). Eur Heart J Suppl 2012. [DOI: 10.1093/eurheartj/sur025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|